Morepen Successfully Clears Fourth Consecutive USFDA Inspection for its Masulkhana Facility with NIL 483 Observation

The milestone arrives at a defining moment for Morepen Labs just weeks after the company disclosed a multi-year CDMO mandate worth approximately Rs. 825 crore (USD 91 million) from a leading global pharma major. “Impeccable clean record with the regulators and a past hattrick of Nil 483 inspections had paved the way for the recent Rs. 825 crore global mandate. The last concluded successful inspection will further drive engagements of similar scale in future,” Mr. Sushil Suri, Chairman and Managing Director, Morepen Laboratories Ltd., said.

Mr. Suri further added,“Global pharmaceutical companies considering long-term manufacturing partnerships do not take quality assurances at face value, they look for strong systems, documentation and more importantly the consistency which these events substantiate.”

“Our consistent track record of NIL 483 inspections is a testament to the strength of our quality systems and our team’s discipline in adhering to the highest global regulatory standards. It strengthens Morepen’s positioning in highly regulated markets by enhancing company’s credibility with global regulators, customers, and partners thus facilitating for long term supply contracts across the globe. Our global orders pipeline only gets stronger from here,” Mr. Sanjay Suri, Executive Director and CEO (API) Morepen Laboratories Limited, claimed.

Morepen Labs is consistently imbibing robust quality management systems, strong data integrity practices, automation, digitization and deep-rooted culture of regulatory compliance in all its manufacturing operations. A large amount of investment has been done by the company in these key areas over the past several years. The Company has consistently aligned its operations with evolving global standards, including current ICH and CFR (Part-21) guidelines, ensuring high levels of product quality, safety, and efficacy as required by global drug regulators. The Company’s focus on digitalization enhances traceability, transparency, and operational efficiency across its manufacturing and quality processes.

As an outcome of these initiatives, Morepen Labs continues to be a preferred partner for global pharmaceutical companies, successfully catering to regulated markets across the US, Europe, and other geographies. Supported by regular and rigorous customer audits, the company exports APIs (Active Pharmaceutical Ingredients) to over 80 countries, aggregating to more than Rs. 670 crores annually. The company is a recognized market leader in six key APIs, with a strong presence in global supply chains. Building on this foundation, the Company is now strategically expanding into the CDMO space, aiming to leverage its regulatory track record, infrastructure, and technical expertise.

About Morepen Laboratories Limited

Morepen Laboratories Ltd. is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering high-quality APIs, having expanded into CDMO space, branded generics, medical devices, and consumer wellness products to over 90 countries worldwide. With a high installed API capacities, a 14 million-strong glucometer user base, and a rapidly expanding digital footprint, Morepen stands at the forefront of India's health-tech evolution. Backed by decades of trust, regulatory approvals from USFDA, WHO, and EU bodies, and a passion for innovation, Morepen is committed to making quality healthcare accessible, affordable, and future-ready.

Morepen Laboratories Limited is a leading pharmaceutical company with a strong presence in APIs, formulations, and home health products. With world-class manufacturing facilities and a global footprint, the Company continues to focus on innovation, quality, and compliance to serve customers across regulated and emerging markets.

Morepen Bags Rs. 825 Crore Global Deal, Expands into High-Growth CDMO Segment

Supplies under the mandate are expected to commence within the next 4–5 months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes.

This engagement marks one of the most significant single CDMO mandates in the Company’s history, as it scales its global manufacturing footprint.

Scaling Long-Term Global Manufacturing Programs

Built on over four decades of API manufacturing expertise and regulatory credibility, Morepen’s CDMO platform enables deeper collaboration with global pharmaceutical innovators through structured, multi-year supply programs.

The mandate reflects the Company’s growing capabilities in regulated markets, supported by internationally accredited facilities including USFDA, WHO-GMP, and EU approvals. With integrated development-to-commercial manufacturing capabilities, Morepen is positioned to support complex scale-ups and long-duration supply frameworks.

The Company continues to evaluate capacity enhancement and technology investments aligned with its expanding CDMO opportunity pipeline.

Mr. Sushil Suri, Chairman & Managing Director, said, “This mandate represents an important milestone in the evolution of Morepen’s manufacturing platform. It reflects the confidence global customers place in our quality systems, regulatory track record, and execution capabilities. Over the years, we have steadily strengthened our infrastructure and compliance depth, enabling participation in larger, long-duration global programs.”

He added, “We view CDMO as a natural extension of our established API strengths, creating additional avenues of scale, stability, and long-term value creation while continuing to reinforce our core businesses.”

Mr. Kushal Suri, President – International Growth (API), added, “This level of customer confidence reflects company’s proven ability to qualify, execute, and deliver under regulated-market expectations. We drove the program end-to-end with technical, regulatory, and commercial scale-up, and delivered a solution built for quality, continuity, and scale. The outcome is clear: Morepen’s credibility is validated, and we are now set to convert this into larger, multi-year global opportunities”

Global pharmaceutical companies are increasingly consolidating supplier networks and partnering with compliant, scalable, and reliable manufacturing platforms capable of long-term supply continuity. Morepen’s vertically integrated API capabilities, regulatory track record, and operational scale position it well to serve this evolving demand

About Morepen

Morepen Laboratories Ltd. is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering high-quality APIs, branded generics, medical devices, and consumer wellness products to over 90 countries worldwide. With ahigh installed API capacities, a 14 million-strong glucometer user base, and a rapidly expanding digital footprint, Morepen stands at the forefront of India's health-tech evolution. Backed by decades of trust, regulatory approvals from USFDA, WHO, and EU bodies, and a passion for innovation, Morepen is committed to making quality healthcare accessible, affordable, and future-ready.

For more details, visit www.morepen.com.

Forward-Looking Statements:

This press release contains forward-looking statements based on current expectations and assumptions regarding anticipated developments and other factors affecting the company. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements.

Q3 FY 26 saw strong performance across its key business segments. CDMO saw a revenue growth of over 16% spurred on by double digit increase in volumes. The international branded formulation segment more than doubled sequentially led by demand recovery across its key markets.

Adj EBITDA increased 21% YoY to Rs 147 cr as better capacity utilization along with a steady ramp up in the newer facilities led to margin improvement. Tighter control over overheads and portfolio rationalization helped mitigate losses in the API and Trade generics segment as well.

Our march towards becoming a global manufacturing company continued unabated with the Company receiving European Union Good Manufacturing Practice (EU GMP) certification for two of its manufacturing facilities. The certification includes the renewal of EU GMP approval for our Oral Solids’ plant and the grant of EU GMP certification for our Oral Liquids Plant. Akums also received its first approval from the UK MHRA for Rivaroxaban tablets

Commenting on the development, Mr. Sandeep Jain, Managing Director, stated, “The EU GMP certifications reflect the strength of our compliant infrastructure, robust quality systems, and the expertise of our skilled teams. We remain focused on disciplined growth while steadily strengthening our presence in regulated markets.”

Mr. Sanjeev Jain, Managing Director, added, “Our continued focus on operational excellence and disciplined growth is aligned with our long-term global vision, enabling us to expand responsibly across regulated markets and strengthen partnerships worldwide.”

Highlights are as under: (Rs in Crores)

Regional Anesthesia & Pain Management (RAPM) Workshop

A joint academic initiative of the Indian Society of Anaesthesiologists (ISA) and Institute of Medical Sciences at Banaras Hindu University (IMS BHU), the workshop was organized with the aim to strengthen clinical competency in Ultrasound‑Guided Regional Anaesthesia (USGRA) through a high‑impact blend of scientific lectures, expert‑led demonstrations, and immersive hands‑on scanning sessions.

Delivered under the academic umbrella of ISA, AORA (Academy of Regional Anaesthesia of India), and ESRA (European Society of Regional Anaesthesia and Pain Therapy), the workshop was attended by over 40 participants. Participants largely comprised of Postgraduate anaesthesia trainees, early-career anaesthesiologists, practicing clinicians seeking skill enhancement in RA, Members of ISA Varanasi and academic institutes. The workshop covered foundational ultrasound principles, postoperative pain management, and comprehensive scanning across upper limb, lower limb, truncal, and abdominal regional blocks

Dr. A.P. Singh, Head of Department for Anaesthesia from BHU Varanasi said, “We are delighted to have partnered with BD India for Scientific Knowledge for World RAPM Day Workshop. BD’s support through their advanced spinal needle and strong medication delivery solutions portfolio, significantly enriched the quality of our academic sessions. Their technology, integrated seamlessly into our hands‑on training modules, enabled participants to gain practical insights that will directly enhance clinical skills and strengthen patient-safety standards.”

Commenting on the RAPM day workshop, Atul Grover, Managing Director, BD India/South Asia said, “BD is proud to be a knowledge partner for the academic initiative spearheaded by Indian Society of Anaesthesiologists and IMS, BHU. We are committed to advancing patient safety and elevating anaesthesia practice across the country by strengthening continuous medical education through partnerships with esteemed medical institutions nationwide. In alignment with our purpose of advancing the world of health, this initiative aims to promote medication‑safety practices to reduce procedural errors and improve patient outcomes.”

About BD-India

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to health care.

The Kapiva R&D Team

With this initiative, Kapiva aims to help build an Ayurveda research ecosystem that matches global pharmaceutical standards. KIF will support work in areas such as novel formulations, standardisation and phytochemistry, AI in Ayurveda, pre-clinical and clinical studies, new extraction technologies, bioactive enhancement, tech-enabled wellness models, etc.

Applications will be invited from research institutions, PhD scholars, clinicians, hospitals, early-stage startups and incubators working in or adjacent to Ayurveda, plant-based therapeutics and integrative health.

The fund is structured to nurture innovation throughout the entire development process. Whether a project is in the initial research phase or nearing commercialisation, KIF will offer the necessary capital, mentorship, and clinical resources. This support system ensures that high-potential scientific ideas are successfully translated into practical, real-world solutions.

Announcing the launch, Ameve Sharma, Founder, Kapiva, said, “For decades, Ayurveda has been seen as either faith-based or purely traditional wisdom. We believe its future lies in being outcome-led and evidence-backed. This fund is a long-term bet on that future. By investing up to Rs. 50 crore in research, collaborations and new technologies, Kapiva wants to help build an ecosystem where Ayurvedic products are developed and tested like modern medicine, yet remain rooted in India’s knowledge systems.”

Dr. R. Govindarajan, Chief Innovation Officer, Kapiva, said, “If Ayurveda has to sit at the same table as modern medicine, it must be tested with the same discipline. At Kapiva we already work with standardised extracts, human trials and AI-driven insights that guide our formulations. Through the Kapiva Innovation Fund we want to open that ecosystem to researchers, clinicians and entrepreneurs, share our infrastructure and mentor high-quality projects, so that robust Ayurvedic science can move from paper to products and reach millions of people.”

Kapiva already runs one of India’s most advanced Ayurveda R&D programmes, with clinical trials on flagship products and a dedicated in-house research team. The company collaborates with leading institutions like Translational Health Science and Technology Institute (Ministry of Science and Technology, GoI), Manipal College of Pharmaceutical Sciences (MCOPS, MAHE), Manipal Hospitals among others on various research projects. As part of this focus on scientific rigour and transparency, Kapiva follows stringent testing protocols across raw materials, packaging and finished products, with several Shilajit-based offerings like the Shilajit Gold Resin, already carrying Certificates of Analysis, and the same standards being progressively extended across its portfolio.

The Kapiva Innovation Fund is now open for applications. Eligible researchers, institutions, clinicians and startups can apply via the dedicated portal. Shortlisted proposals will be evaluated by a panel of Kapiva’s R&D leadership and external domain experts on scientific rigour, novelty, feasibility, and potential to improve health outcomes at scale.

Applicants can learn more about the fund, submit their proposals, and track their application status through a dedicated portal on Kapiva’s website: innovation.kapiva.in.

About Kapiva

Kapiva is a modern, homegrown Ayurvedic D2C brand on a mission to make evidence-based Ayurveda simple, modern, and accessible for everyday wellness. Backed by a dedicated R&D vertical of scientists and researchers, Kapiva develops authentic formulations using science-backed Ayurveda, standardised herbs, and high-quality ingredients. Kapiva has been a disruptor in the Ayurvedic industry by introducing innovation in product formats that can be easily integrated into people's daily routines. Kapiva has expanded globally with its wholly owned subsidiaries in the USA and Middle East, and has a strong offline presence across 50,000+ stores in India.

Website: www.kapiva.in.

Research and development of novel pharma IP could be a key component for a stronger pharma workforce in India
 

Under the agreement, APCARL will provide Havih access to advanced R&D laboratories and underground Biosafety Level 4 (BSL-4) biocontainment facilities at its Pulivendula campus in YSR Kadapa district. Havih will develop and supply next-generation anti-infective medicines for early use within Andhra Pradesh, with manufacturing and export centered in India.
 

"Prime Minister Modi's Viksit Bharat @ 2047 vision recognizes that long-term national growth depends on moving up the value chain toward high-margin innovation that creates globally competitive wages for India's people. India's economic growth has created momentum; the next phase requires branded pharmaceutical research, advanced IP creation and indigenous scientific leadership.

Havih's partnership with the Government of Andhra Pradesh and APCARL directly advances that vision by building India-owned biocontainment research, first-in-class drug innovation and export-ready pharmaceutical IP. This collaboration is an investment in India's scientists, engineers and future innovators - and a practical step toward India's leadership in global health security," said Scotch McClure, Chairman of Havih Envirosciences.
 

About Havih Envirosciences

Havih Envirosciences Pvt. Ltd. is an Indian citizen-owned and operated life sciences and environmental health company focused on India-first innovation in advanced anti-infective medicines, biosafety solutions and environmental resilience technologies. Established to build indigenous scientific capability and high-value intellectual property, Havih serves as a platform for translating cutting-edge research into globally competitive products developed and manufactured in India.
 

Havih's mission is to strengthen India's leadership in branded pharmaceutical research and development by enabling high-margin innovation, advanced containment research and workforce upskilling aligned with national priorities such as Viksit Bharat @ 2047, Make in India and Atmanirbhar Bharat. The company emphasizes biosafety, biodefense and public-health preparedness while supporting international export markets from an India-based innovation core.
 

Through strategic collaborations with government research institutions and global technology partners, Havih is building a next-generation R&D and production ecosystem designed to deliver durable economic value, globally relevant IP and higher-skilled, higher-wage scientific employment for India's growing workforce.
 

About Maxwell Biosciences

Maxwell Biosciences is a global health technology company pioneering a new category of immune-inspired small molecules called Claromers®. Designed to mimic and enhance the body's natural defenses, Claromers® destroy pathogenic bacteria, viruses, fungi and biofilms-without harming healthy cells or the microbiome.
 

Originally developed for critical infectious diseases, Maxwell's technology is now entering commercial deployment across cosmetics, personal care, medical coatings and biodefense. Claromers® require no refrigeration and are highly stable in even the harshest environments.
 

Backed by a decade of research, a robust patent portfolio and leadership with deep expertise in science, military, AI and global health, Maxwell has active collaborative agreements with the US military and governments worldwide. FDA clinical trials are planned for 2026. Non-pharmaceutical commercialization is underway, with pilot access for select partners.
 

Maxwell's AI-first platform enables rapid innovation against the rising threat of resistant pathogens, offering scalable, shelf-stable and microbiome-resilient solutions for a healthier planet.
 

To learn more about Maxwell Biosciences, visit MaxwellBiosciences.com, or follow us on X and LinkedIn.
 

Contacts

Media
press@maxwellbiosciences.com

Investors
investor.relations@maxwellbiosciences.com

Inaugural Ceremony of Centre of Excellence in Reproductive Genomics​
 

This strategic collaboration leverages Anderson Diagnostics’ decade of deep expertise in reproductive genomics to fundamentally change the landscape of “prenatal testing” and “women’s healthcare diagnostics” across coastal Karnataka and beyond.
 

The Centre marks a significant milestone by establishing a first-of-its-kind, state-of-the-art Next-Generation Sequencing (NGS) facility in-house at the University Hospital — designed to support comprehensive diagnostic services across all institutions under the MAHE umbrella.

This initiative is specifically designed to introduce advanced genomic solutions focused on reproductive health, enabling the diagnosis of critical diseases before the birth of a child — a crucial advancement in women's healthcare.

Bridging Research and Real-World Diagnostics 

The core mission of the COE is to integrate cutting-edge academic research with robust, scalable clinical diagnostics — thereby impacting reproductive and foetal medicine.

Addressing the specific expertise brought to the partnership, Dr. Suriyakumar G, Director & Radiologist, Anderson Diagnostics & Labs, stated:

“Anderson Diagnostics is bringing over ten years of pioneering experience specifically in ‘Reproductive Genomics’ and high-throughput testing to this collaboration. Our role is to establish the operational backbone — guaranteeing that the cutting-edge research originating from the MAHE-Anderson COE translates reliably and rapidly into actionable diagnostic reports for patients. We are committed to setting new benchmarks in standardised processes — ensuring that this joint venture can change the dynamics of the genomics diagnostics ecosystem, especially concerning complex prenatal scenarios.”

 MAHE-Anderson COE will serve as a hub for academic training, translational research, and comprehensive diagnostic services available to all institutions under the MAHE umbrella and other hospitals in the region.

Dr. Sharath K. Rao, Pro Vice-Chancellor (Health Sciences), MAHE, Manipal, lauded the synergistic nature of the tie-up, “We are pleased to partner with Anderson Diagnostics & Labs, Chennai - one of the pioneers in delivering advanced diagnostic services across India and neighbouring countries. This collaboration provides an excellent opportunity to expand access to cost-effective genomic solutions and strengthen healthcare delivery in coastal Karnataka.”

Dr. Anil K. Bhat, Dean, Kasturba Medical College, Manipal, highlighted the importance of the industry-academia linkage, “We are glad to be a part of this remarkable initiative. The Centre’s efforts in offering advanced genomic healthcare solutions will enable more personalised clinical management in reproductive and foetal medicine.”

Dr. Shubhashree Uppangala, Associate Professor and Head of the Department (Reproductive Sciences), Kasturba Medical College, Manipal, and Coordinator for the MAHE-Anderson COE, emphasised the centre’s broader mission as the vital bridge between the two entities, “The Centre aims to bridge the current knowledge gap related to genomic diagnostic solutions in reproductive health and to support the development of precision medicine and research in women’s health and reproduction.”

About Anderson Diagnostics & Labs
Anderson Diagnostics & Labs is a leading name in advanced diagnostics - renowned for its commitment to innovation, quality standards, and expanding access to specialised testing across India for over a decade.

About MAHE (Manipal Academy of Higher Education) 
MAHE is a leading “multi-disciplinary university” with a strong emphasis on health sciences education, research, and patient care through its constituent institutions - including Kasturba Medical College.
 

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

The CDMO segment remained the key contributor with revenue of Rs. 804 crore. Volumes for the CDMO vertical grew 7% y-o-y, as against muted industry volume growth, reflecting Akums’ position as preferred CMDO partner in India. The domestic Branded Formulations business recorded revenue of Rs. 122 crore, with EBITDA margins improving to 21.6%, supported by focused portfolio management. The Branded Export segment, although had seasonal impact from various countries, maintained healthy EBITDA margin of 24.5%,

For the quarter ended September 30, 2025, Akums reported consolidated revenue of Rs. 1,018 crore compared to Rs. 1,024 crore in Q1 FY26 and Rs. 1,033 crore in Q2 FY25. The EBITDA stood at Rs. 94 crore with a margin of 9.3%. The PAT was Rs. 43 crore. For the first half of FY26, revenue stood at Rs. 2,042 crore with an EBITDA of Rs. 223 crore (margin of 10.9%) and PAT of Rs. 107 crore.

The Hon’ble President of Zambia recently did ground breaking of the pharmaceutical plant, set up as a joint venture between Akums and the Govt. of The Republic of Zambia. This marks a significant step in expanding Akums’ global reach. The Zambian facility is aimed at supporting access to quality medicines across the SADC Countries, with product range across multiple therapeutic areas and dosage forms.

Another milestone Akums achieved recently was the first commercial supply of formulations in Europe, with the supply of Dapagliflozin tablets to Switzerland. Akums will also supply Rivaroxaban tablets in Europe in Q3. The European contract for oral liquid supply is on track with Plant 2 undergoing EU-GMP Audit in October.

Commenting on the quarterly performance, Mr. Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals Ltd., said, “Our performance this quarter reflects our focus on long-term priorities in a dynamic business environment. The developments in Zambia and Europe mark important milestones in our ongoing journey of becoming a global CDMO.”

Mr. Sandeep Jain, Managing Director, Akums Drugs & Pharmaceuticals Ltd., added, “CDMO business is navigating through a complex phase, with continued weakening of API prices and sustained flat volumes in the industry. Akums has outpaced industry volume growth. we remain focused on delivering long term shareholder value by further cementing our leadership position in CDMO business, taking measures to grow our domestic and exports branded business and curtailing losses in API and trade generics.”

Highlights are as Follows:

SMT’s Occluder devices used for closure of congenital and structural heart defects

The Cocoon Occluder portfolio from SMT offers catheter-based devices for the closure of all four types of defects through a minimally invasive approach. Each device is engineered with SMT’s proprietary platinum coating technology, providing biocompatibility and fluoroscopic visibility to ensure precise placement and long-term outcomes.

Recent global clinical studies continue to validate the safety and efficacy of the Cocoon Occluder family:

• Cocoon Septal Occluder demonstrated a >99% acute closure rate with no device-related adverse events at 43-month follow-up, as reported in the Hellenic Journal of Cardiology [2021;62(3):206–211]³, reaffirming its long-term safety and effectiveness for ASD closure.

• Cocoon PFO Occluder demonstrated a >98% acute closure rate with no major complications, according to findings in the Hellenic Journal of Cardiology [2024;75:21–25]⁴, underscoring its consistent performance and favourable clinical outcomes.

Over the past two decades, Cocoon devices have been successfully implanted, benefiting both paediatric and adult patients across 47 countries (as of March 31, 2025).

Continuing its mission to advance cardiovascular care, SMT will soon initiate the SAFE-PFO randomized controlled trial, enrolling 1,260 patients across Europe and the UK. This study will directly compare the Cocoon PFO Occluder with the Amplatzer PFO Closure Device Family, aiming to further strengthen clinical evidence for treatment of PFO patients with a history of stroke.

Bhargav Kotadia, CEO, Sahajanand Medical Technologies, said, “The Cocoon journey has been about impact. Over the past 20 years, our devices have been implanted in more than 100,000 patients, offering children and adults a safer, less invasive option for treating congenital & structural heart defects. As we look ahead, SMT remains committed to advancing cardiovascular care and saving lives worldwide.”

About SMT (Sahajanand Medical Technologies)
SMT (Sahajanand Medical Technologies) is a medical devices company with a portfolio of technologically advanced medical devices across vascular and structural heart intervention. SMT offers an extensive portfolio of products focusing on vascular intervention and was the first company in the world to receive CE certification for a DES with a biodegradable polymer. SMT has a global presence with its footprints in more than 75 countries, as on March 31, 2025.

For further updates, please the website or follow SMT on LinkedIn.

References: 

1. www.pubmed.ncbi.nlm.nih.gov/40454242

2. www.ncbi.nlm.nih.gov/books/NBK493151

3. www.pubmed.ncbi.nlm.nih.gov/33484876

4. www,pubmed.ncbi.nlm.nih.gov/37127207

Disclaimer
Sahajanand Medical Technologies Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, an initial public offer of its equity shares and has filed a draft red herring prospectus dated July 25, 2025 (“DRHP”) with the Securities and Exchange Board of India (“SEBI”) and the stock exchanges. The DRHP is available on our website at www.smtpl.com as well as on the website of SEBI at www.sebi.gov.in, Motilal Oswal Investment Advisors Limited at www.motilaloswalgroup.com, Avendus Capital Private Limited at www.avendus.com, HSBC Securities and Capital Markets (India) Private Limited at www.business.hsbc.co.in and Nuvama Wealth Management Limited at www.nuvama.com and and the websites of the stock exchange(s) at www.nseindia.com and www.bseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and refer to the Red Herring Prospectus, including the section titled “Risk Factors” of the Red Herring Prospectus when available, for details. Potential investors should not rely on the DRHP for any investment decision.

Amplatzer™ Occluder devices are registered trademarks of Abbott or its subsidiaries. 

MrMed Bengaluru Hub

As diabetes and obesity continue to rise at an alarming rate, with over 100 million people in India living with diabetes, the need for reliable access to advanced therapies has never been more critical. MrMed’s Bengaluru hub addresses this challenge by ensuring same-day cold-chain delivery for eligible GLP-1 orders within the city and faster dispatches to surrounding regions including Karnataka, Telangana, Kerala, and Tamil Nadu.

Bringing Chronic Care Closer to Patients

GLP-1 drugs are highly temperature-sensitive and must be stored between 2–8°C to preserve their potency. Even a short temperature variation can reduce their effectiveness and affect a patient’s treatment progress.

“India is entering a new phase of chronic care, and patients deserve timely access to advanced therapies without worrying about potency loss or delivery delays,” said Devashish Singh, Co-founder and CEO of MrMed. “This hub reflects our mission to ensure that no patient loses a day of therapy because of logistics barriers. We’re bringing dependable specialty care closer to patients and caregivers across South India.”

For patients managing long-term conditions like diabetes, cancer, or autoimmune diseases, consistent access to genuine and temperature-controlled medicines can make a world of difference. By improving delivery speed and reliability, MrMed aims to reduce anxiety around missed doses and help patients stay on therapy without interruption.

Designed for Precision and Safety

The Bengaluru facility is equipped with advanced cold-chain systems designed to maintain end-to-end temperature control from warehouse to doorstep. The infrastructure includes:

• Temperature Controlled Logistics to ensure every order stays within 2–8°C.

• Insulated storage zones and validated packaging for delicate biologics and injectables.

• Trained pharma logistics teams specializing in the handling of GLP-1 agonists such as semaglutide, dulaglutide, and tirzepatide.

“Our systems are built to protect drug potency at every step,” said Saurab Jain, Co-founder and CBO of MrMed. “Whether it’s GLP-1 delivery in Bengaluru or faster regional fulfillment, our goal is to combine speed with precision. Through route optimization, real-time tracking, and an expert delivery network, we’re ensuring that every patient receives their medicine on time and in perfect condition.”

Supporting Broader Access to Specialty Medicines

Beyond GLP-1 therapies, the new hub will cater to a wide range of critical and chronic care treatments, including oncology, nephrology, immunology, and endocrinology. This marks MrMed’s third major distribution center, following Chennai and Delhi, further expanding its national cold-chain footprint.

By strengthening its southern network, MrMed continues its mission of bridging the gap between advanced healthcare and patient accessibility. Each hub plays a crucial role in ensuring that genuine medicines reach patients quickly, securely, and under optimal storage conditions.

Empowering Patients with Trust and Transparency

Founded in 2021 by Devashish Singh and Saurab Jain, MrMed has rapidly emerged as India’s most trusted platform for chronic and critical care medicines. The company focuses on delivering authentic medicines, patient-first service, and complete visibility from order to delivery.

MrMed’s emphasis on clinical integrity, safety, and convenience has made it a preferred choice for thousands of patients managing long-term therapies. With the launch of the Bengaluru cold-chain hub, the company takes another step forward in its mission to make advanced care accessible, reliable, and stress-free for every Indian household.

About MrMed

MrMed is India’s largest online super-specialty pharmacy focused on chronic and critical care treatments across oncology, endocrinology, nephrology, gastroenterology, and other complex therapy areas. Founded in 2021, MrMed is committed to improving treatment access through authentic medicines, cold-chain enabled delivery, transparent processes, and dedicated patient support.

Website: www.mrmed.in.

(L-R) Sunil Sinha, Founder & CEO, Ignite Excellence DMCC and Soumitra Bhattacharya, CEO & Director, IFQM at IFQM Symposium 2025

The IFQM second annual symposium brainstormed on the core issue of MSMEs' challenges of adopting, practising, achieving and developing a quality culture and their immense potential to contribute to various industries, especially in IT (Artificial Intelligence), Pharma, Health, Education and Automobile. A galaxy of senior industry leaders explored the strengths, weaknesses, opportunities, and areas of engagement and improvement.

The broad questions that IFQM posed to the experts during the two days included: How does India ramp up to World Class Quality? What is Total Quality? What lessons for business are from the disciplines of fine arts? What does it take to succeed globally in the electronics and semiconductor industry? How can India improve access to quality healthcare and superior infrastructure? Transforming the MSME sector through Quality, Innovation and Excellence. How to rise in the Pharma Value Chain. How does the learning from Quality plus Innovation in Design and Manufacturing help MSMEs face and manage their challenges? Can a crisis act as a catalyst for National resurgence? What actions are required to integrate the Academia - Industry ways of work? 

The sessions also examined the strategies to strengthen India's global competitiveness across critical sectors, like advancing pharmaceuticals through innovative therapeutics and health sciences, scaling electronics and semiconductors, and expanding access to quality healthcare and infrastructure. Dr. Noriaki Kano emphasised that lasting innovation must be anchored in quality and continuous improvement. In a participative engagement through historical context, Dr Kano shared insights as a creator of a Quality Model. He informed that more training sessions on TQM will be undertaken for the MSMEs, including visits to the JUSE institute in Japan.

The biggest takeaways from the second annual IFQM Symposium 2025 focused on a central theme, "Quality & Innovation to Make India Globally Competitive.”

Mr Soumitra Bhattacharya, CEO & Director, IFQM, said “We just concluded the IFQM Symposium, which to my mind is a remarkable step forward from where we started. A confluence of all stakeholders, nearly 450 of them – from policy makers to Business leaders from organizations both large and small, Leaders from the Academia consisting of Deans and professors from reputed educational institutions, students representing the future talent and many others who have India up in their minds. We all have a unified intention to carve out a path for India to be globally competitive. IFQM is fast evolving as an Industry led-Nation first movement, gaining pace and momentum by the day. The Symposium urged organizations to invest in the future, adopt Quality as a strategy, and thereby create value that makes India an economic super power, a place it richly deserves to be. The Symposium has fueled ambition, promise and confidence for IFQM to grow multifold, atleast 5X in the following year, with newer platforms, programs and projects that integrate these stakeholders, by adopting Digital as a force multiplier.”

A unique session on the lessons industry and businesses can incorporate from the disciplines of Fine Arts highlighted the methods to develop empathy, excellence, ambition, collaboration, discipline, mentorship (guru), and sensitivity.

Commenting on the importance of investment by the industry, in the sectoral growth -- Surinder Singh, Advisor, Technology India Semiconductor Mission ISM stated that the industry has a bigger role in innovation, quality and talent growth. Dr Devi Shetty, chairman and founder of Narayana Health, suggested that the way forward is for employers to push employees to have health insurance partly funded in India. That must happen with the organised and unorganised sectors. He said that India could become the first country in the world to dissociate health care from wealth and prove that the nation's or family's wealth has nothing to do with the quality of health care its citizens will enjoy within the next decade.

The two-day symposium was attended by government leaders, global experts, industry champions, and academia to deliberate on an action agenda for positioning India as a trusted, world-class player in global value chains. IFQM is led by a Governing Council* consisting of top industry captains.

About IFQM 
Instituted in the year 2023, IFQM is the Indian Federation for Quality Management that is committed to the promotion of transformative changes across Indian industries. It seeks to institutionalise a culture of quality that meets and exceeds global standards. It is about bringing in continuous improvements of both products and services, thereby elevating the perception about Brand India. Committed to the prosperity and quality of life of all, IFQM functions as a catalyst in making Indian businesses globally respected with cooperative trust, respect, empathy, and mutual sharing. Through its initiatives, IFQM supports India's journey towards becoming a developed nation by 2047, with an emphasis on innovation, excellence, and stakeholder engagement across sectors.

*The IFQM Governing Council: • Mr. N. Chandrasekaran, Chairman, Tata Sons • Mr. Dilip Sanghvi, MD, Sun Pharmaceuticals • Ms. Kiran Mazumdar Shaw, Executive Chairperson, Biocon Biologics • Mr. TV Narendran, CEO & MD, Tata Steel Limited • Mr. K.N. Radhakrishnan, Director & CEO, TVS Motor Co • Dr. Randhir Thakur, CEO & MD, Tata Electronics Pvt. Ltd. • Mr. Salil Gupte, President, Boeing India & South Asia • Mr. SN Subrahmanyan, Chairman & MD, Larsen & Toubro • Mr. Venu Srinivasan, Chairman Emeritus, TVS Motor Co & Chairman, IFQM • Mr. Vivek Chaand Sehgal, Chairman and Co-Founder, Motherson Group.

IFQM on Web: https: ifqm.org.in
IFQM Events: events.ifqm.org.in
IFQM on social media: www.linkedin.com/company/ifqm

Changing patient behaviour towards prescription to drive unimaginable savings

The Everyday Cost Burden of Medicines
India’s healthcare system places a heavy financial load on patients. According to National Health Accounts data, households paid nearly 40% of total health expenditures out-of-pocket in 2021–22, a slight improvement from previous years, but still among the highest globally. Medicines account for the largest portion of this burden. Research shows that over half of household health spending in India goes to purchasing medicines.

This situation disproportionately affects people managing chronic diseases like diabetes, cardiovascular conditions, and cancer. Even when generics are available, scepticism.

around their quality leads many patients to stick with expensive branded options, increasing their monthly financial stress.

Why Many Still Choose Branded Drugs
A 2023 study on medicine perception in India revealed that a majority of patients prefer branded drugs over generics. The main reasons? Concerns about quality, trust, and lack of transparent product information. According to PwC and Deloitte, closing the awareness gap and improving trust in generics is crucial for lowering healthcare costs across emerging markets.

Despite being bioequivalent, generics often suffer from a credibility deficit. Without clear labelling, pricing transparency, or pharmacist validation, most patients hesitate to make the switch.

How Medkart Makes Generics Work for Everyone
Founded in 2014, Medkart chose to solve this trust problem head-on. Its business model is centred on high-quality generics, verified sources, and a tech-first platform to help patients make informed choices. The company doesn’t list branded options—it offers verified generic alternatives and tells you how much you’re saving.

Its app and website include a price comparison engine that shows users how much they could save by switching to generics. These tools break down composition, strength, and pricing side-by-side. Most users report savings between 50% and 85% depending on the medicine.

For example, the antifungal medicine Voriconazole (Vorier), often used in cancer recovery, typically sells for nearly INR 5,000 or more. Medkart provides an equally effective alternative for just INR 720—a saving of 86%.

What Sets Medkart Apart
Medkart’s biggest value is its backend quality assurance. Every product sold is “Medkart Assured”—meaning it is sourced only from manufacturers compliant with Schedule-M, India’s GMP standard. The company performs audits and checks to ensure the quality before it reaches the shelves or customer homes.

Another distinguishing factor is its omnichannel presence. Medkart operates over 100+ physical stores and offers delivery across 35,000+ pin codes. Whether someone orders through its app, website, or even WhatsApp, they receive pharmacist-reviewed support and affordable medicines at their doorstep.

The company has served more than 12 lakh families to date and has processed over XX lakh orders.

Patient-First, Data-Driven Future
Medkart's inventory system is built on predictive restocking: if a store sells even one strip of Glimepiride+Metformin, the system triggers a refill based on projected demand. This ensures shelves are never empty of critical medicines. According to Markets & Data, India’s pharmaceutical logistics market, valued at ₹30,000 crore, is undergoing rapid digital transformation, making models like Medkart highly scalable.

Why Medkart Has Stayed Under the Radar
Unlike most health-tech brands, Medkart hasn’t pursued massive ad budgets or influencer campaigns. It has grown organically by focusing on consumer trust, consistent pricing, and word-of-mouth advocacy. For patients who switch to Medkart, the savings are immediate, and the transparency is rare in this industry.

Medkart’s impact is measurable: saving over INR 650 crore cumulatively and around  INR 300 crore annually for Indian families. These are not offers—they’re structural savings built into its supply chain and generic-first approach.

Rethinking the Role of a Pharmacy in India
At a time when India is dealing with rising cases of lifestyle diseases, patients need continuity, affordability, and ease. Medkart is one of the few pharmacy chains designed to deliver all three, without compromising on quality. It is not just selling medicine. It’s building a more transparent, accessible healthcare system—one order at a time.

Explore Smart Savings Today
Visit www.medkart.in or download the Medkart App to compare prices, send a prescription via WhatsApp, and order Medkart Assured generics directly to your home.

Choosing Branded Generics Made Simple & Easy
 

The Industry Context: Healthcare Costs and E-Pharmacy Boom
India’s healthcare system places a significant financial burden on individuals, with many patients still covering treatment costs themselves. According to the National Health Accounts Estimates 2021–22 released by the Ministry of Health and Family Welfare, out-of-pocket expenditure accounted for approximately 39.4% of total health spending, down from 62.6% in 2014–15, but still substantial. This is particularly challenging for families managing chronic conditions like diabetes or hypertension, where monthly medicine expenses quickly add up but there is hardly any insurance that covers it. Meanwhile, a widespread lack of awareness persists: many patients are still unaware that most branded drugs have affordable generic counterparts, regulated for safety and efficacy by India’s pharmaceutical standards.
 

Moreover, while generic medicines make up nearly 70% of India’s pharma volume, a persistent perception problem remains: Are they as good as brands? Can they be trusted? These doubts, often fueled by misinformation and inconsistent supply chains, have kept many patients from making the switch.
 

Medkart is changing that.

What Medkart Solves: A System Plagued by Price Confusion and Inequity

Despite the availability of generics, most Indian consumers continue to purchase costly branded medicines due to a lack of information, trust, or local access. Chronic disease patients – especially those with diabetes or hypertension, which account for approximately 68% of India’s chronic illness burden are hit hardest by monthly bills.
 

Many tier-2 and rural customers also struggle with access. A patient needing basic chronic meds often travels kilometres, pays for branded substitutes, and ends up spending nearly 30% of household income on drugs alone.

Medkart: India’s Smartest Generic App Platform

Medkart’s app is designed as the simplest platform to use for smart medicine buying

• Generic Medicine Comparison Engine: India’s first price-comparison tool for generics lets users compare prices and compositions instantly. Voriconazole, a multipurpose drug, shows savings of up to 86% (MRP Rs. 5,192 vs Medkart’s price Rs. 720).

• Chronic Disease Navigation: Medicines are categorised into disease buckets (Diabetes, BP, Kidney, Heart), aligned with India’s leading disease burdens.

• Prescription Upload & Matching: Users upload their prescription, and the app matches it with “Medkart Assured” generics, tested for Schedule M compliance and plant-audited.

• WhatsApp Integration: With nearly 600M Indian WhatsApp users, Medkart offers order placement via WhatsApp, breaking digital barriers for older and rural patients.

• Store + Delivery Hybrid Model: With 100+ retail stores and coverage across 35,000+ pin codes, Medkart offers online delivery with COD or many ways to pay.

Scale and Impact

• Savings Delivered: Rs. 650 crore saved across 11+ lac users

• Reach: 60 lakh orders fulfilled; 11+ Lac families served

• Coverage: 35,000+ pincodes – deeper than most e-pharmacies

• App Features: Available in Hindi, English, and Gujarati

Smarter Pharmacy, Healthier India
With India’s generic medicine market gaining momentum and digital health adoption rising across Tier 2 and Tier 3 cities, Medkart is bridging critical gaps in access, trust, and affordability. Its transparent pricing, disease-specific drug discovery, and hybrid delivery-retail model empower patients to make informed choices without compromising on quality.
 

As the demand for affordable healthcare surges, Medkart is not just responding, it's reshaping how India buys medicines. By building India’s smartest generic pharmacy platform, Medkart is making quality healthcare both accessible and sustainable for millions.
 

Switch smart, save more. Download the Medkart App or visit www.medkart.in to explore up to 85% savings on generics.
 

Medkart – Aapka Shubhchintak.

Medkart audit team ensuring WHO-GMP and Schedule M compliance for Assuring quality

“Price matters—but quality is non-negotiable. Medkart ensures every medicine on our shelves not only saves you money but also meets India’s highest manufacturing and safety standards,” said Ankur Agarwal, Co-founder of Medkart.

The Generic Dilemma: Cost vs. Confidence

India’s generic drug market, valued at over USD 24 billion as per Invest India, continues to face consumer trust issues domestically. A 2025 study published in the European Journal of Clinical Pharmacology reported that patients often harbour doubts about the safety and effectiveness of generics, particularly in oncology and cardiovascular segments. The study emphasizes that inconsistent communication by healthcare providers and a lack of robust manufacturer-level visibility are key barriers to trust. Moreover, WHO-backed reviews have highlighted that enforcement of quality regulations—especially in smaller manufacturing units—is uneven, contributing to a fragmented trust ecosystem. These systemic challenges, combined with low awareness and historical overreliance on branded drugs, reinforce the incorrect perception that affordability comes at the cost of efficacy.

What Is Schedule M—and Why It Matters

To combat this, Medkart has aligned all its procurement processes with Schedule M of the Drugs and Cosmetics Act—a stringent regulatory guideline that specifies Good Manufacturing Practices (GMP) for pharmaceutical production. Schedule M, as outlined by the Indian Pharmaceutical Alliance (Schedule M-1 Guidelines), covers standards for equipment, hygiene, storage, testing, and documentation—ensuring that every medicine manufactured is traceable and safe for consumption.

Medkart Assured: Going Beyond Certification

Medkart's multi-layered quality assurance process includes:

• Plant Audits: Medkart independently conducts regular plant audits of all partnered manufacturers to ensure international quality norms.

• Compulsory Dual Testing: Quality checks are run twice on all products at NABL accredited third-party labs to monitor consistency.

• Medkart Assured Tag: Only after passing all quality thresholds is a product marked “Medkart Assured” in-store and online.

“We’ve built Medkart Assured so patients never have to choose between affordability and safety,” said Parasharan Chari, Co-founder of Medkart. “Our commitment to Schedule M compliance, independent audits, and third-party testing gives consumers confidence that every medicine they take is backed by rigorous validation.”

Raising the Bar on Public Trust

In an ecosystem where trust is as important as pricing, Medkart’s dual focus on education and assurance is helping reshape public opinion. The Medkart app includes a powerful Medicine-to-Medicine comparison tool, enabling users to make informed decisions with ease. Pharmacists are trained not just to dispense but to explain quality differences and clear doubts.

Download With Confidence

Patients deserve affordability without anxiety. Visit www.medkart.in or download the Medkart App on-Play Store or App Store to compare medicines, upload prescriptions, and order Medkart Assured medicines—generic, yes, but never second best.

Medkart is creating a platform where women lead with knowledge, empathy, and impact in retail healthcare

This gender gap is especially visible in the pharmacy sector, despite the fact that women already form the majority of healthcare decision influencers in households. Most pharmacy store owners continue to be male, even though India produces over 150,000 pharmacy graduates annually, with many qualified women unable to transition into business due to lack of support or structure.

In response, Medkart Pharmacy — one of India’s fastest-growing pharmacy retail chains — has announced a women-first franchise campaign to empower aspiring female entrepreneurs to become local health leaders. The initiative is designed to offer women a low-risk, structured path to business ownership in the high-impact healthcare space.

Founded in 2014, Medkart operates 100+ stores across Gujarat, Rajasthan, and Maharashtra, and has helped over 10 lakh families save ₹650 crore on essential medicines. The company’s model promotes WHO-GMP certified generic drugs and operates on a transparent, education-first approach to retail pharmacy. Visit medkartfranchise.in for More Details.
 

One of the biggest frustrations for customers seeking affordable treatment is that they often cannot get their full prescription filled at one store — especially when they ask for generic alternatives. Medkart solves this by offering both branded and generic medicines under one roof, eliminating the need to visit multiple chemists or compromise on affordability. Customers save time, money, and get trusted options in a single visit.

The Medkart franchise system requires an all-inclusive investment of Rs. 8–9 lakhs. It includes everything from store setup, inventory, and branding, to staff recruitment, licensing, training, and a proprietary AI-powered inventory management dashboard. This software provides real-time analytics on stock levels, expiry tracking, billing, and demand forecasts — allowing franchisees to run lean, efficient, compliant and technology-enabled businesses.

“Inventory losses are one of the biggest reasons why small pharmacies fail,” said Ankur Agarwal, Co-founder and CEO of Medkart. “We built our franchise model to eliminate that fear entirely. Partners receive the stock they need, when they need it — and anything that doesn’t move is taken back.”

“Our goal is to simplify healthcare retail,” added Parasharan Chari, Co-founder and COO. “We’re making it easier for individuals — even without pharma experience — to own and operate clean, transparent medicine stores that actually help their communities. Women, in particular, bring empathy, discipline, and trust — qualities that are invaluable in healthcare entrepreneurship — and we’re proud to be creating a platform where they can thrive.”

Under this new campaign, women franchisees will receive additional mentorship, priority onboarding, and access to Medkart’s Franchisee Academy — a structured training program covering medicine knowledge, customer interaction, business compliance, and use of Medkart’s tech platform. The brand reports that most franchise partners reach breakeven within 3–6 months, with ROI typically achieved within the first year and a half.

As India moves toward greater inclusion in healthcare entrepreneurship, Medkart’s women-first initiative is a step toward ensuring that more women take on leadership roles in the health sector — not just as caregivers, but as business builders and community anchors.

For franchise inquiries, visit www.medkart.in/franchise or email bd@medkart.in.
 

Chandigarh University Uttar Pradesh Officials After Receiving the Approval Letter from Pharmacy Council of India for Kick Starting Programs in Pharmacy at CU UP Campus

The School of Pharmacy at CU Uttar Pradesh has been conceptualized with a future-ready educational model aligned with industry demands and driven by cutting-edge technology. The curriculum is designed to balance theoretical foundations with hands-on training, ensuring that students graduate as competent and industry-ready healthcare professionals. The Pharmacy Council of India has granted formal approval to Chandigarh University, Lucknow Campus to begin offering 60 seats in the Pharmacy course from the academic session 2025.

State-of-the-Art Infrastructure for Research-Driven Learning

The School of Pharmacy offers an infrastructure tailored for advanced research. Students actively participate in projects related to pharmacokinetics, clinical pharmacy, medicinal chemistry, and toxicology. The curriculum has been crafted in collaboration with international industry experts and academicians, enabling students to grasp both traditional and emerging subjects with clarity while sharpening their skills in line with global standards.

The availability of AI-powered tools and modern laboratories encourages experiential learning. Students also engage in internships, research assignments, and community-driven projects, making education at CU not only theoretical but deeply practical and immersive.

A Booming Sector with Expanding Opportunities

With the global pharmaceutical industry projected to grow at an estimated rate of 4.7% from 2024 to 2029—reaching a market size of approximately USD 1,454 billion—career prospects in pharmacy remain robust. Recognizing this trend, Chandigarh University has developed an ecosystem equipped with high-tech labs, experienced industry professionals, and collaborative learning environments to prepare a skilled and adaptable workforce.

Industry-Collaborated Education for Future-Ready Professionals

Students at the School of Pharmacy can pursue careers in diverse fields such as Clinical Research, Intellectual Property Management, Regulatory Affairs, Quality Control, and Medical Writing. The university also imparts regulatory training in Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), and Good Clinical Practices (GCP), ensuring graduates are prepared to work in highly regulated environments.

Chandigarh University, Uttar Pradesh, stands as a model of integrated education where learning, technology, and industry interface seamlessly. Students not only receive rigorous academic instruction but also benefit from industry training, internships, and research exposure, preparing them for a balanced and successful career.

The university's AI-supported, modern campus in Unnao—backed by industry-aligned curriculum, advanced labs, and seasoned faculty—provides a solid academic foundation. Strategic partnerships with leading companies and government bodies further enhance student opportunities by offering essential skill training and diverse career pathways.

Academic Leadership at the Helm

The school is led by Prof. (Dr.) Amit Verma. Prof. Verma is accompanied by rich international, industry, and academic experience. Having more than 20 years of pharmaceutical education, research, and industrial experience, Prof. Verma has made notable contributions towards international collaborations, drug development plans, regulatory documentation, and innovation in pharmaceutical sciences. He has collaborated with India's and the world's premier institutions and pharmaceutical industries, providing his services in drug discovery, formulation science, regulatory affairs, clinical research and academic leadership. His passion for pharmacy education is evident in his strong desire for interactive learning, digital integration, research mentorship, and international academic collaborations.

Being the India's first AI-enabled campus Chandigarh University Uttar Pradesh is committed to revolutionize education through modern technology. This smart campus offers AI-powered learning platforms, real-time simulation, virtual labs, that foster an environment of incubation, innovation and critical thinking. The university believe in quality professional education where the eminent faculty on roll are equipped with advanced pedagogy to produce pharmacy professionals to not only adept in their field but also competent in leveraging technology to enhance patient care and drug development. This initiative and commitment ensure our dedication to shape future-ready pharmacy leaders to meet healthcare industry requirement.

Backed with the legacy of Chandigarh University Mohali, students will get an opportunity for the international exposure through the collaborations with over 150 foreign universities, enriching their academic and cultural perspectives. Chandigarh University Uttar Pradesh is committed to nurturing competent and compassionate pharmacy professionals who can contribute meaningfully to the global healthcare ecosystem”.

About Chandigarh University Uttar Pradesh (Lucknow)

Envisioned to foster a culture of sustainability and empower future global leaders, Chandigarh University, Uttar Pradesh, immerses 21st-century learners in a personalised and experiential learning experience, integrating an AI-powered academic model and a multidimensional, futuristic perspective on education. Our Uttar Pradesh campus carries forward the venerable legacy of more than a decade of Chandigarh University, Punjab, which has established itself as India's No. 1 Private University and a torchbearer of groundbreaking pedagogy and research-driven innovation. The AI-augmented new campus offers a broad spectrum of industry-driven futuristic academic programs encompassing data-driven insights, virtual reality experiences, real-world simulations, corporate mentorship, international perspective, interdisciplinary research, cultivation of entrepreneurial spirit, and professional competencies.

Website: www.culko.in.

In Q4 FY25, Akums reported revenue of Rs.1,073 crore, reflecting a robust 12.4% year-on-year (YoY) growth. The company posted a 10.4% EBITDA margin. Building on its Q4 momentum, Akums closed FY25 with consolidated total income of Rs. 4,170 crore and an adjusted EBITDA margin of 12.3%, a 7-basis point improvement from the previous year. The company continued its focus on enhancing its product mix, building a differentiated, research-driven portfolio, and expanding its global presence.

One of the key developments during the fiscal year was securing an approx. €200 million contract for the manufacture and supply of pharmaceutical products to regulated European markets — a milestone that significantly expands Akums’ global CDMO footprint. The commercial supplies for this will begin in 2027. To support its expanding footprint, Akums invested Rs. 272 crore in capital expenditure during FY25. which now stands at 49.6 billion units annually. This infrastructure scale-up ensures readiness for large-scale domestic CDMO operations as well as global pharma opportunities.

Akums also maintained a strong R&D focus, investing Rs. 130 crore which is over 3% of revenue. With 973 DCGI approvals now, the company’s product portfolio has over 4,000 commercialized formulations. This is across multiple therapeutic areas across 60+ dosage forms.

Segmental Performance Overview

Akums’ flagship business, CDMO, contributed ~78% to the group turnover with an adjusted EBITDA of 14.1% in FY 25. The company’s domestic branded formulation business segment reported ~9% growth while international branded formulation business grew by ~14%. Trade generics and API segment continue to be in operational loss this fiscal, but the company is taking firm measures to cut the losses in the coming fiscal.

Strategic Focus and Future Outlook

Despite making meaningful progress across key business segments, Akums reported flat year-on-year revenue, largely due to muted industry volumes and price erosion in APIs. The company, however, continued to invest in long-term growth drivers to consolidate its leadership position in India’s pharmaceutical landscape and lay the foundation for global CDMO expansion.

With an R&D spend, up 16% from FY24, Akums continues to deepen its innovation capabilities, develop complex formulations, and enrich its portfolio. The company’s emphasis on quality-focused manufacturing, novel delivery formats, and patient-centric innovations ensures that its offerings are both globally relevant and therapeutically effective.

Commenting on the results, Mr. Sanjeev Jain, Managing Director, said, " As we look back on the year we got listed, we also look ahead with a renewed sense of purpose. Our entry into Europe is a pivotal step for the Akums’ global CDMO expansion. Coupled with strategic capacity expansion and a sharp focus on differentiated offerings, we are laying the foundation for Akums to emerge as a trusted global CDMO. We remain steadfast in our commitment to creating long-term value for all stakeholders and to delivering healthcare solutions that impact lives across geographies."

Mr. Sandeep Jain, Managing Director, added, "It gives us immense pride to close FY25 on a positive note, especially in a year marked by volatility across the pharmaceutical industry. Despite price erosion in APIs and slowing volumes, Akums remained focused on the fundamentals—operational discipline, innovation, and global ambition. Our new injectable facility is now operational, our R&D engine is stronger than ever, and our differentiated portfolio continues to resonate with partners. These are exciting times, as we accelerate our transformation into a global pharmaceutical manufacturing organization."

Here is the Summary of Profit and Loss Statement for reference

Refrigeration Not Required—India’s First Room-Temperature Nicorandil is here
 

Addressing Storage Challenges in Cardiac Medications
Nicorandil is widely prescribed for the treatment of chronic stable angina. Due to its sensitivity to temperature and humidity, its storage has traditionally required stringent cold-chain logistics. This requirement often poses significant challenges, especially in rural and semi-urban areas where maintaining cold-chain infrastructure is difficult.
 

Enhancing Affordability and Accessibility
Medkart's room-temperature stable Nicorandil tablets are manufactured under WHO-GMP-certified facilities, ensuring high-quality standards. By eliminating the need for refrigeration, the company significantly reduces distribution costs, allowing the medication to be priced up to 80% lower than its branded counterparts.

"Our room-stable Nicorandil is more than a product—it’s an answer to India’s cold chain problem in heart care," said Ankur Agarwal, Co-founder of Medkart. "We're proving that innovation doesn't have to be expensive—it has to be relevant."
 

Dr Ramesh Mehta, a senior cardiologist based in Ahmedabad, added, "Ensuring that a cardiac drug like Nicorandil remains effective without refrigeration is a major step forward, particularly for patients in remote regions. We’ve long seen efficacy compromised due to storage issues. This advancement will save lives and improve treatment consistency."
 

Tackling the Cardiovascular Disease Burden
Cardiovascular diseases (CVDs) are a leading cause of mortality in India. According to the Global Burden of Disease Study, heart disease is the leading cause of death among women in India, accounting for almost 18% of all female deaths. Medkart’s launch addresses both cost and accessibility in one formulation.
 

Product Availability
Medkart’s room-stable Nicorandil tablets are now available at over 35000+ pincodes and online at www.medkart.in.
 

To illustrate the cost difference between branded and Medkart's generic versions of Nicorandil tablets, here’s a comparative snapshot based on real-time Medkart data:
 

*Prices are based on current Medkart data. Actual savings may vary.

About Medkart
Founded in 2014, Medkart is committed to making affordable healthcare accessible to all—especially for chronic conditions like heart disease, diabetes, and hypertension where long-term medication is critical. With a growing network of over 100+ retail outlets across India and a seamless online platform, Medkart empowers people to compare medicine prices, access WHO-GMP-certified generics, and receive reliable guidance from trained pharmacists.
 

Having served over 11 lakh families and facilitated savings of more than Rs. 600 crore to date, Medkart leverages a tech-first approach through tools like dosage comparison, molecule-based search, store locator, and in-app ordering. Grounded in transparency and trust, Medkart continues to redefine India’s pharmaceutical ecosystem by making quality treatment affordable for all.

Panel session
 

The symposium highlighted seasonal influenza's disproportionate effects on high-risk groups, particularly adults aged 65+, and those with chronic conditions like diabetes and cardiovascular diseases. Prof. Sasisopin Kiertiburanakul, from Mahidol University and Vice President of the Infectious Disease Association of Thailand delivered the keynote on regional influenza epidemiology.

Recent WHO data shows influenza affects approximately 1 billion people annually worldwide. with 3-5 million severe cases, resulting in 290,000-650,000 deaths globally.

"These figures are particularly alarming for vulnerable populations. Influenza can trigger severe complications including pneumonia, myocardial infarction, worsen existing conditions and lead to death," said Prof. Sasisopin Kiertiburanakul. "Safeguarding vulnerable people with flu vaccination is safe and effective. Evidence shows it significantly reduces hospitalizations and mortality among our most vulnerable people. It represents a sound investment in public health."

The event featured interactive sessions where medical experts from Thailand, Malaysia and Vietnam discussed the critical importance of influenza vaccination for high-risk groups, including people with cardiovascular disease, diabetes, and older adults. Despite diverse attitudes towards vaccines, experts emphasized that improving access to flu immunization and implementing effective, evidence-based communication strategies are key to reach WHO's target of 75% influenza vaccination coverage among high-risk populations.

"At Sanofi, we believe protecting vulnerable groups against flu requires a well-rounded approach. Through this symposium, we're empowering healthcare professionals with the tools and knowledge they need to better protect those most at risk in our communities," emphasized Ruby Dizon, Vaccines Medical Head of Sanofi Southeast Asia and India.

Participants gained practical insights on addressing common misconceptions about influenza prevention and learned techniques for framing conversations around the specific benefits for high-risk patients. The symposium concluded with a call to action urging healthcare professionals to unite in protecting vulnerable groups through appropriate flu vaccination.

For high-risk individuals, protection against influenza isn't just a routine health measure—it's protection beyond flu including against potentially devastating complications. Through this initiative, Sanofi continues its commitment to reducing the global burden of influenza by supporting healthcare professionals with evidence-based strategies and combating misinformation about flu vaccinations to improve quality of life.

Digital Boost to Government effort for Generic Drugs

Despite these efforts, out-of-pocket expenditure (OOPE) remains a significant concern, accounting for 39.4% of total health expenditure in 2021–22 Ministry of Health and Family Welfare. This financial burden underscores the need for increased public awareness and trust in generic medicines.

That’s where digital healthcare platforms like Medkart step in.

Rather than just being a supplier, Medkart acts as an enabler of informed healthcare decisions. It complements government policies by promoting awareness, improving accessibility, and increasing the adoption of WHO-GMP-certified generic medicines. With an expansive retail presence and a user-focused digital platform, Medkart ensures that affordability is matched by trust and transparency.

Medkart’s unmatched range of generic medicines goes above and beyond any pharmacy chain in the country, ensuring users always have options—no matter how specific or uncommon the prescription. Its expansive catalogue is one of the largest in India’s pharma retail space.

How Medkart Supports Government Health Missions:

• Enhancing Jan Aushadhi Yojana: Medkart offers high-quality generics at prices comparable to Jan Aushadhi rates, ensuring affordability.

• Advancing Ayushman Bharat Goals: By reducing OOPE through affordable generics, Medkart aids in preventing financial hardship due to medical expenses.

• Making finding alternatives easy for the Public: Through digital modules and pharmacists it becomes easier to find an alternative for the prescribed brand or molecule (Something which is unprecedented), In the process Medkart empowers consumers to make informed choices.

• Comprehensive Range : Medkart’s range of generics spans across all therapeutic categories from Chronic/Acute to Cancers. Basically the entire spectrum of molecules available in the country is available with Medkart.

Whether it’s a diabetic managing long-term care or a family in a Tier-2 city seeking affordable antibiotics, Medkart's platform simplifies healthcare decisions and amplifies government impact. Users can search for their medicines either by brand name as prescribed by their doctor or by the molecule or combination, making it easier for both digitally-savvy users and first-time generic adopters to navigate. They can compare prices in seconds, locate nearby stores, and even consult a pharmacist for free.

"Affordable care isn’t just about lower prices—it’s about empowering every Indian to access quality treatment with confidence. That’s what Medkart stands for,” says Ankur Agarwal, Co-founder of Medkart Pharmacy.

About Medkart Pharmacy

Medkart is India's fastest-growing generic pharmacy chain, committed to affordability, education, and transparency. Since 2014, it has empowered over 11 lakh families to save more than ₹600 crore on medicines through WHO-GMP-certified generics. With a presence in 100+ stores across 20+ cities and a powerful digital ecosystem via www.medkart.in, Medkart bridges the gap between policy and access, making smart healthcare a daily reality.

Closing CTA

As India embraces generics to create a healthier tomorrow, visit www.medkart.in to explore how Medkart is helping transform intent into impact—one prescription at a time.

Let’s make affordable care not just a policy, but a practice.

India's First Generic Medicine Comparison Engine Goes Live: Medkart Pharmacy Leads the Way
 

Bridging the Knowledge Gap

Generic medicines, which contain the same active ingredients as their branded counterparts, offer a cost-effective alternative without compromising efficacy. However, a lack of awareness and prevailing misconceptions have hindered their widespread adoption in India. Medkart's new platform addresses this challenge by offering a user-friendly interface where individuals can:
 

• Compare Prices: Evaluate the cost differences between branded and generic medicines.

• Understand Compositions: Access detailed information on drug compositions and therapeutic uses. The level of detailing at Medkart is unprecedented as it is the only platform to provide and map the release pattern between two medicines.

• Identify Alternatives: Discover generic substitutes for prescribed branded medications.
  ​

By facilitating easy comparisons, Medkart aims to demystify generic medicines and improve their acceptance among the masses.
 

A Vision Rooted in Affordability

Founded in 2014 by Ankur Agarwal and Parasharan Chari, Medkart Pharmacy has consistently championed the cause of affordable healthcare. With over 100 retail outlets across Gujarat and Rajasthan along with a robust online presence www.medkart.in, the company has served more than 11 lakh families, helping them save an estimated Rs. 650 crores on medicine expenses till date.
 

"Our mission has always been to make quality healthcare accessible and affordable. By launching this comparison engine, we're taking a significant step towards empowering consumers with the knowledge they need to make cost-effective choices," said Ankur Agarwal, Co-founder of Medkart Pharmacy.
 

"If a diabetic patient has been prescribed Empagliflozin, they can simply search the brand name or the molecule name and get all the alternatives available, and compare the prices," explained Parasharan Chari, Co-founder of Medkart. "This will enable the consumer to make an informed decision and be rest assured of the quality as each generic medicine retailed on Medkart is from WHO-GMP certified manufacturers."​
 

Features Tailored for the Indian Consumer

Understanding the diverse needs of Indian consumers, Medkart's platform offers:

• Multilingual Support: Available in English, Hindi, and Gujarati to cater to a broader audience.

• Mobile Accessibility: A dedicated app allows users to compare and order medicines on-the-go.

• Authenticity Assurance: All medicines are WHO-GMP certified, ensuring quality and safety.
  ​

Aligning with National Healthcare Goals

Medkart's initiative resonates with the Indian government's emphasis on promoting generic medicines to reduce healthcare costs. By providing a transparent platform for comparison, Medkart not only aids consumers but also supports national objectives of making healthcare more affordable and accessible.
 

Looking Ahead
As healthcare costs continue to rise, tools that offer clarity and choice become indispensable. Medkart Pharmacy's comparison engine stands as a testament to the power of technology in bridging gaps and fostering informed decisions. With plans to expand its reach and features, Medkart is poised to play a pivotal role in reshaping India's pharmaceutical landscape.
 

For more information or to explore the comparison tool, visit www.medkart.in/compare-medicines.

This strategic move is poised to enhance Florricks Lifecare's global footprint, driving innovation and growth in the pharmaceutical industry. The partnerships aim to leverage Florricks Lifecare's expertise in cutting-edge pharmaceutical solutions, bolstering its presence and capabilities in these critical regions.

Dr. Salim Shaikh, Managing Director & CEO, Florricks Lifecare Private Limited

Dr. Salim Shaikh, Managing Director & CEO of Florricks Lifecare Private Limited stated, "This collaboration represents a pivotal moment for our company as we expand our global reach and strengthen our commitment to delivering high-quality pharmaceutical products. The investment underscores our dedication to innovation and excellence in the healthcare sector. Florricks Lifecare continues to lead the way in developing advanced pharmaceutical solutions that cater to the evolving needs of patients and healthcare professionals worldwide. With this significant investment, the company is set to make substantial strides in research, development, and production, ensuring the highest standards of quality and safety.”. Established with a vision to make a difference in healthcare, Florricks Lifecare has grown to become a recognized leader in sourcing and supplying Active Pharmaceutical Ingredients (APIs) and intermediates to pharmaceutical manufacturers and healthcare providers worldwide," said Dr. Salim Shaikh.

Announcing the historic moment, Mr. Lalit Singh, Executive Director of Florricks Lifecare Private Limited, stated, "Florricks Lifecare’s hybrid supplying and global sourcing model for ingredients and raw materials delivers the most flexible and reliable solutions for our customers’ unique manufacturing requirements. We offer the flexibility to supply or source difficult-to-find ingredients and materials, supported by industry-leading standards of quality documentation and regulatory compliance. This investment will propel Florricks Lifecare to further expand our global expansion."

This strategic move is poised to enhance Florricks Lifecare's global footprint, driving innovation and growth in the pharmaceutical industry. The partnerships aim to leverage Florricks Lifecare's expertise in cutting-edge pharmaceutical solutions, bolstering its presence and capabilities in these critical regions.

Mr. Lalit Singh, also remarked, "This collaboration represents a pivotal moment for our company as we expand our global reach and strengthen our commitment to delivering high-quality pharmaceutical products. The investment underscores our dedication to innovation and excellence in the healthcare sector."

Florricks Lifecare continues to lead the way in developing advanced pharmaceutical solutions that cater to the evolving needs of patients and healthcare professionals worldwide. With this significant investment, the company is set to make substantial strides in research, development, and production, ensuring the highest standards of quality and safety.

About Florricks Lifecare Private Limited

Florricks Lifecare Private Limited, headquartered in Mumbai, India, stands as a leading global player in the pharmaceutical industry with a widespread international presence. We specialize in a diverse range of products, including Pharmaceutical APIs, Finished Formulations, Critical Raw Materials, Advanced Intermediates, Impurities, Pellets, and Nutraceuticals. Florricks Lifecare offerings cater to the Life Sciences, Specialty Chemicals, and Agriscience industries, ensuring comprehensive solutions for Florricks Lifecare clients worldwide.

With over a decade of invaluable experience, Florricks Lifecare has established a robust presence in over 45 countries across Asia, Europe, Africa, North America, and South America. Florricks Lifecare has an international network of offices and partnerships underscores Florricks Lifecare’s commitment to delivering high-quality pharmaceutical products and services on a global scale. Florricks Lifecare Private Limited is an ISO-compliant company, adhering to the highest standards of quality and safety. Florricks Lifecare has collaborative manufacturing facilities boast certifications from WHO-GMP, KFDA, PMDA, EU-GMP, USFDA, and other regulatory bodies, ensuring that Florricks Lifecare products meet stringent international standards. Florricks Lifecare has a dedicated R&D team committed to developing cutting-edge Pharmaceutical Formulations, APIs, Surgical, Veterinary, Herbal, and Nutraceutical Products. This relentless pursuit of innovation allows Florricks Lifecare to stay ahead of industry trends and meet the evolving needs of Florricks Lifecare clients.

Dancy Labs Private Limited

Announcing the investment of USD 120 Million Dr Ashok Tiwari Managing Director of the unlisted pharma company Dansy Labs Pvt Limited said, " We are thrilled to share that the Board of Directors and Management have endorsed this pivotal proposal in our recent Special General Meeting. This strategic investment will open up significant opportunities in key markets across Sweden. With the capital raised from investors and NBFCs, we are poised to seize this deal and realize its full potential. The asset buyout & Patents is a critical component of Dansy Labs' broader strategy to expand its global footprint. The acquired assets include state-of-the-art research facilities and cutting-edge technologies that will be integrated into Dansy Labs' existing operations. This expansion is set to accelerate the development of novel pharmaceutical solutions and solidify the company's position as a leader in the industry. With the acquisition, Dansy Labs aims to bolster its innovative capabilities and enhance its competitive edge. The new assets will provide the company with advanced manufacturing capabilities and resources to drive pioneering research in various therapeutic areas. This strategic move is expected to lead to a surge in patent filings and the development of breakthrough treatments that address unmet medical needs."

Mr Chandrakant Patil Executive Director of Dansy Labs Pvt Limited said, "This strategic asset buyout is a transformative step for Dansy Labs. It reflects our unwavering commitment to advancing research and innovation in the pharmaceutical industry. By integrating these world-class assets, we are poised to accelerate the development of cutting-edge therapies and expand our global reach. Dansy Labs has long been recognized for its commitment to quality and excellence in the pharmaceutical industry. The company's robust portfolio of active pharmaceutical ingredients (APIs) and intermediates has garnered acclaim for its superior quality and efficacy. The latest acquisition underscores Dansy Labs' dedication to maintaining high standards and delivering innovative solutions that improve patient outcomes. The asset buyout is expected to have a profound impact on Dansy Labs' research and development efforts. The company is set to leverage the newly acquired assets to explore novel therapeutic avenues and develop treatments that address critical health challenges. As Dansy Labs continues to push the boundaries of innovation, it remains dedicated to improving the quality of life for patients worldwide. The investment aligns with Dansy Labs' mission to enhance its global footprint and strengthen its position in the pharmaceutical and healthcare sectors. By integrating these new assets, the company aims to accelerate its development of cutting-edge solutions and maintain its competitive edge in the industry."

Dansy Labs Private Limited, headquartered in Mumbai, India, is a leading player in the pharmaceutical industry. The company specializes in the import and export of active pharmaceutical ingredients (APIs) and intermediates. With a strong focus on research and innovation, Dansy Labs is committed to delivering high-quality solutions that meet the evolving needs of the global healthcare market.

About Dansy Labs
Dansy Labs is a leading global pharmaceutical company dedicated to transforming industries through innovation and excellence. With a diverse portfolio of cutting-edge products and solutions in Pharmaceutical API’s, Dansy Labs is committed to driving progress and shaping the future of technology. Dansy Labs has a significant presence in pharmaceutical Active Pharmaceutical Ingredient (API) research, particularly focused on developing innovative and sustainable methods for producing high- quality APIs, often leveraging its expertise in biotechnology, chemistry, and advanced manufacturing technologies; key areas of focus include developing new APIs for complex diseases. Dansy Labs Pvt Ltd, based in Mumbai—the commercial capital of India—stands as a beacon of pharmaceutical research and innovation. Founded with the mission to transform the pharmaceutical landscape, Dansy Labs has carved a significant niche for itself in the realm of Active Pharmaceutical Ingredient (API) research.

As one of the pioneering API manufacturing and marketing facilities in the world, Dansy Labs Pvt Ltd continues to push the boundaries of what’s possible in pharmaceutical research. The company’s vision is to harness the power of technology and innovation to improve lives and create a sustainable future. By focusing on cutting-edge research and customer-centric development, Dansy Labs is poised to remain at the forefront of pharmaceutical advancements for years to come.

Dansy labs Private limited
OFFICE NO 53-54, Kalpataru Complex,CG Rd, Chembur, Mumbai, Maharashtra 400074
www.dansylab.com.
EMAIL: info@dansylab.com 

Jubilant Biosys Innovative Research Services Pte. Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, has executed the transaction definitive agreements with Pierre Fabre SA, and its affiliate entities (“PF”), for JBIRSPL to acquire 80% equity capital in JASMIN (new company incorporated by PF in France, as a Societe par Actions Simplifiee (SAS)), with remaining 20% retained by PF.

 R&D center at Saint-Julien-en-Genevois, France

At closing of the transaction, JASMIN shall acquire Pierre Fabre’s R&D Centre (including R&D Site and R&D activities) at Saint-Julien-en-Genevois, France, and JBIRSPL would also execute a Shareholders’ Agreement and other transition agreements with PF.

Strategic Rationale
This strategic agreement will enable Jubilant Biosys Limited to expand its footprint in Europe in areas like Biologics (mAbs) and Antibody Drug Conjugate (ADC), in addition to its existing services including integrated drug discovery services from India

• Expands Jubilant’s addressable market in the fast-growing (20%+ CAGR) ADC/XDC segment: Expands Jubilant’s addressable market in ADC CDMO to ~$1.4 Bn. Next gen XDCs pipeline is also growing rapidly

• Enhances Jubilant Biosys Limited’s domain expertise in ADC with expanded chemistry capabilities: Complements Jubilant Biosys Limited’s payload expertise with payload-linker synthesis, bioconjugation and analytical services

• PF team have deep ADC/XDC expertise: Core team with decades of ADC experience, with history of successfully delivering several clinical candidates

• Provides strategic footprint in EU: An opportunity to significantly expand our customer connections with large pharmaceutical companies due to proximity to EU/US markets, which have a preference for local CRO interactions

• Brings together a complementary innovator customer base: The collaboration will help create significant cross-selling potential to customer bases across small-to-mid biotech and large innovator pharma

• Unique & cost-effective delivery model: Integrating the scientific expertise in Biologics at the Saint-Julien-en- Genevois site with that of small molecules at Jubilant will provide a unique & cost-effective delivery model to EU & US Companies.

Speaking on the announcement, Giuliano Perfetti, CEO & Managing Director, Jubilant Biosys Limited said, “We are thrilled to have reached this strategic agreement with Pierre Fabre. Our R&D site in Saint-Julien-en-Genevois will serve as a Center of Excellence for biologics and ADCs, located at the heart of Europe. This expansion strengthens our presence and fosters collaboration with both biotech and large pharma companies in Europe and the USA. By combining the scientific expertise in biologics and ADCs at Saint-Julien-en-Genevois with the capabilities of 1,200 scientists in India we establish a comprehensive service offering for accelerated delivery of early chemistry, discovery biology, DMPK, integrated drug discovery and CDMO for intermediates and APIs. With this strategic move, Jubilant Biosys Limited advances its "CRDMO Partner in Science" strategy and reinforces its commitment to delivering innovative solutions to global pharmaceutical customers.”

About Jubilant Biosys Limited
Jubilant Biosys Limited provides drug discovery and contract development and manufacturing services to global pharmaceutical and biotech companies. The service offering includes drug discovery services, mg to Kilo, non-GMP and GMP scale up of novel compounds, intermediates and NCEs. The business operates from Bengaluru, Noida and Greater Noida in India, offering integrated and functional drug discovery and development services to global innovators. Jubilant Biosys Limited has demonstrated expertise in functional services in chemistry including computational, medicinal/ synthetic chemistry, PR&D and GMP scale-up capabilities up to phase II. Services in biology include structural biology, in-vitro biology, DMPK, in-vivo pharmacology and Toxicology. Further, Jubilant Biosys Limited has integrated discovery expertise with a track record of working on over 85 programs in multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation, CNS and expanding into Rare Diseases.

About Jubilant Pharmova Limited
Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company with global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses. In the Radiopharma business, the Company is involved in manufacturing and supply of Radiopharmaceuticals with a network of 46 radiopharmacies in the US. The Company’s Allergy Immunotherapy business is involved in the manufacturing and supply of allergic extracts and venom products in the US and in some other markets such as Canada, Europe and Australia. Jubilant through its CDMO Sterile Injectable business offers manufacturing services including sterile fill and finish injectable (both liquid and lyophilization), full-service ophthalmic offer (liquids, ointments & creams) and ampoules. The CRDMO business of the Company includes the Drug Discovery Services business that provides contract research and development services through two world class research centers in Bengaluru and Noida in India and the CDMO-API business that is involved in the manufacturing of Active Pharmaceutical Ingredients. Jubilant Therapeutics is involved in Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. The Company operates multiple manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Jubilant Pharmova Limited has a team of around 5,500 multicultural people across the globe. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals companies globally.

Brief about Pierre Fabre
Laboratoires Pierre Fabre, established in 1961 by pharmacist Pierre Fabre, is a leading French multinational company headquartered in Castres, France. Specializing in pharmaceuticals and dermo-cosmetics, the company has grown to employ over 10,000 people worldwide. In 2023, the company reported revenues exceeding €2.8 billion, with 70% of sales generated internationally. Renowned for its innovation in oncology and dermatology, Pierre Fabre has become a significant global player in the healthcare and beauty industries.

The Research Centre in Saint-Julien-en-Genevois was founded by Pierre Fabre in January 1990. It specializes in immuno-oncology, with a focus on immunomodulatory macrophage biomedicines. Over the years, it has also developed a strong expertise in biological drugs, naked antibodies, and antibody-drug conjugates (ADCs). Located near Geneva and immerged in a particularly buoyant pharmaceutical innovation ecosystem on both sides of the border, the site enjoys state-of-the-art expertise and equipment and is pursuing several research projects on the reactivation of macrophage activity in case of cancer inhibition.

Disclaimer
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova Limited may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

‘Saint-Julien-en-Genevois’ refers to - “Saint-Julien-en-Genevois at the France/Switzerland border”

Fharmacy Bazaar Expands Its Digital Franchise Network

Fharmacy Bazaar currently operates 20 omni-channel retail stores in Eastern India and has announced ambitious plans to expand to 200 stores by the end of 2027. Additionally, the company is launching a Digital Franchisee Network, targeting 500 digital franchisees by 2030. This initiative not only aims to enhance the availability of affordable healthcare products but also provides lucrative opportunities for aspiring entrepreneurs. The company’s robust digital infrastructure, which includes its e-commerce platform www.pharmacybazar.in and mobile apps for Android and iOS, ensures seamless access to healthcare products for customers nationwide.

In the FMCG sector, Fharmacy Bazaar has established itself as a trusted name with its popular King’s Coin edible oil brand, which has become a household staple. Expanding its portfolio, the company now offers Soya Chunks and Instant Noodles, catering to the evolving needs of Indian consumers. This diversification demonstrates Fharmacy Bazaar’s commitment to providing high-quality, affordable products across multiple categories.

To support its growth and expansion plans, Fharmacy Bazaar’s board has approved an SME IPO, marking a significant milestone in the company’s journey. The IPO will help the company raise the necessary capital to fuel its ambitious vision of becoming a household name in both healthcare and FMCG sectors. With its innovative approach, strong legacy, and commitment to community empowerment, Fharmacy Bazaar is poised to set new benchmarks in the industry.

For more information, visit www.pharmacybazar.in.

Avantor team being felicitated by APEX Officials
 

Apex India Foundation is a Non-Profit Foundation that aims to recognize and celebrate exemplary individuals and organizations for outstanding contributions in the field of environmental protection, safety in the workplace, implementation of Corporate Social Responsibility, and adopting human resources best practices. The purpose of the “Occupational Health & Safety Awards” is to reward organizations that have made unique contributions in the field of health and safety of workers.
 

"We are proud of the dual recognition by the esteemed Apex India Foundation for our health and safety standards and our unwavering commitment to the well-being of our associates,” said Yee Seng, Vice President, Operations, AMEA, Avantor. “These awards are a testament to the hard work of our Environmental Health, Safety, Sustainability and Security (EHSS&S) team and Avantor’s leadership position in the life sciences industry.”
 

Commenting on the awards, Puneet Pant, Managing Director, India, Avantor said, “We are extremely honored to receive this recognition. Our safety strategy emphasizes proactive monitoring of regulatory changes, partnering with operational leaders to meet internal health and safety requirements, eliminating hazards, and reducing risks. Ensuring the safety and well-being of our associates is our top priority, and this recognition underscores our commitment to creating a safe and healthy work environment.”

Victorious Avantor team (L to R): Himanshu Dimri, Dr. Mahesh Gore and Hemang Kantilal Hajariwala 
 

Earlier this year, Avantor’s Panoli site was also recognized with the Ankleshwar Environmental Preservation Society (AEPS) Safety Excellence Gold Award. The AEPS Safety Excellence Awards, initiated this year, sought to identify, and honor companies that exhibit exceptional dedication to safety, through comprehensive assessments and historical performance evaluations.
 

The health, safety and well-being of its associates is a top priority for Avantor. Its comprehensive approach prioritizes support for the whole person - their physical, mental and emotional health - and it continually strives to have the best possible policies and procedures in place to ensure all aspects of its associates' well-being.

About Avantor

Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

Sebamed, the German skincare expert brand marketed by USV Pvt. Ltd - a leader in cardio-diabetic healthcare in India, unveils its transformative new campaign, ‘Project Skin Deep’.

Sebamed’s latest campaign ‘Project Skin Deep’

A Vision Beneath the Surface

In a world where beauty campaigns are content to stop at the mirror, Sebamed dares to venture further - 3mm further, to be exact. ‘Project Skin Deep’ is no ordinary skincare campaign, it’s a paradigm shift. The campaign begins where few dare to look: under the microscope, zooming into the layers of skin to question if beauty really is skin deep. The answer, as it turns out, is a rather satisfying yes.

The campaign reveals a series of breathtaking images: vivid, microscopic landscapes of healthy skin before and after Sebamed’s products. Captured in striking, almost celestial hues, these microscopic images are testimonies of what healthy skin looks like when science works. For decades, beauty campaigns have relied on glamour shots, clever lighting, and cleverer editing. Sebamed flips the script. This is beauty without makeup, both figuratively and literally. Because, as Sebamed seems to remind us, skin doesn’t lie - even under a microscope.

Where Science Becomes Art

While some might say science and art live in separate worlds, Sebamed begs to differ. The campaign is where science becomes art. Every microscopic detail is proof of Sebamed’s pH-balanced formulations in action, repairing and protecting skin at its very foundation.

Spanning platforms from digital screens to billboards, Sebamed’s call resounds across mediums, even your subconscious, sparking a movement in consumers to demand better from their skincare. Produced in collaboration with Leo Burnett, the campaign marries creativity with scientific precision, crafting a narrative that redefines beauty standards.

Karan Goel, Marketing Head, Sebamed India (USV Pvt. Ltd.), shares, “Too often, skincare campaigns focus solely on immediate visible results. At Sebamed, we believe true beauty stems from healthy skin - inside and out. This campaign empowers consumers with the knowledge that long-term skin health is the foundation of lasting beauty. ‘Project Skin Deep’ underscores our unwavering commitment to science-backed skincare and informed choices.”

Sachin Kamble, Co. Chief Creative Officer, Leo Burnett - South Asia, adds, “With ‘Project Skin Deep’ we took the bold step of doing an actual biopsy of a skin cell before and after using Sebamed products and then went on to integrate it into the visual narrative of the campaign. Each image is a glimpse into how beautiful, complex yet intriguing each skin cell is and the profound impact of Sebamed. At Burnett we believe in the power of authenticity in storytelling and this campaign is the best example integrating science, design, technology and creativity.”

Key Campaign Highlights

• Campaign Video: www.youtube.com/watch?v=G7JQ9B05Ru8&ab_channel=SebamedIndia

• Campaign BTS Video: youtu.be/Cs7OwgD_bFo?si=B3cBGvB9MPEWCP-n

• Directed by: John Fedrick, Prodigious

About Sebamed

Sebamed Products are marketed in India by USV Private Limited. USV Private Limited is a leading pharmaceutical player with over six decades of impeccable legacy driven by its Credo values and commands leadership positions in diabetes and cardiac therapeutic segments in India.

Sanjeev Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd., Right - Rajesh N. Jagdale, Managing Director of Jagdale Group

Together, Akums and JIL aims to revolutionize the market by introducing innovative, non-milk-based aseptic carton packing solutions across key categories like a) wellness drinks under food, Ayush and nutraceutical frameworks, b) Sports nutrition with essential electrolytes for hydration and recovery c) Nutritional products for critical care, diabetes, and weight management.

India's Ready-to-Drink market is witnessing a significant surge as consumers increasingly prioritize health, convenience, and quality. With this partnership, Akums and Jagdale will deliver products that seamlessly integrate health benefits with superior Aseptic packaging technology,” said Sanjeev Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd. “Aseptic packing solutions ensure the highest standards of safety, shelf stability, and nutrient retention, meeting the evolving needs of modern consumers.”

The collaboration represents a strategic convergence of Akums’ strong and extensive clients base and Jagdale’s legacy in healthcare innovation. Rajesh N. Jagdale, Managing Director of Jagdale Group, emphasized the potential impact of this alliance. “We are excited to partner with Akums, a name synonymous with trust and quality. Together, we aim to redefine the ready-to-drink segment in India, catering to diverse consumer needs across mass, premium, and medical markets. Our focus on non-milk-based formulations ensures inclusivity and addresses a broad spectrum of dietary preferences and prophylactic requirements.”

The electrolyte RTD market in India, valued at over Rs. 1,000 crores with more than 150 million packs sold annually, is experiencing robust growth. With a steady 10% annual increase in volume, this market sees heightened demand, particularly during the summer months, when hydration needs peak. Simultaneously, the broader Indian RTD market is witnessing significant expansion, driven by a rising preference for functional beverages, therapeutic drinks, and wellness products. Aseptic carton packing technology is at the forefront of this evolution, offering solutions that meet the demands of modern consumers.

By employing advanced aseptic processing and packaging, products benefit from an extended shelf life, remaining fresh and safe for consumption without requiring refrigeration—a crucial advantage in India’s diverse climatic conditions. Furthermore, this technology ensures the preservation of essential nutrients, making it ideal for health-conscious consumers seeking wellness-focused beverages.

Additionally, aseptic packs are designed with sustainability in mind, being lightweight, and eco-friendly, which appeals to the growing segment of environmentally conscious consumers. These attributes collectively position aseptic carton packs as a game-changer in the RTD market, meeting modern demands while paving the way for a healthier, more sustainable future.

With a projected focus on mass-market accessibility and premium health-driven offerings, the partnership also taps into underserved medical markets, including critical care nutrition and therapy support products. This holistic approach positions the tie-up as a catalyst for change in the healthcare and wellness landscape.

Akums and JIL aims to address India’s burgeoning demand for nutraceuticals, functional beverages, and therapeutic solutions. As the partnership evolves, both organizations envision contributing significantly to the health and wellness revolution while fostering a sustainable ecosystem. The launch of the aseptic carton pack product line marks the beginning of a transformative journey, setting new benchmarks for quality, innovation, and consumer satisfaction.

The Arya Vaidya Pharmacy - Product Portfolio
 

"At AVP, our focus extends beyond products – it is about nurturing a connection with each consumer through the timeless values of Ayurveda,” said Shri C. Devidas Varier, MD, AVP. “We believe in blending our Ayurvedic legacy and tradition with innovation, creating offerings that honor our heritage while adapting to modern needs, thus promoting holistic wellness that resonates across generations.”

Expanding Ayurvedic Wellness: A Product for Every Need

The Consumer Business Division (CBD) introduces a thoughtfully curated range of products designed to meet diverse wellness needs, reflecting AVP’s commitment to making Ayurvedic care accessible across major cities in India. The range covers a broad spectrum, including hair care solutions to face and skin care products and pain relief formulations. In addition, immunity and wellness products and the newly launched baby care segment offers authentic Ayurvedic solutions reinforcing the goodness of this holistic science.

“In today’s world, wellness must be as adaptable and convenient as it is effective, and that’s where we see the future of Ayurveda," said Mr. Vipin Vijay, CEO, AVP. "This is not just about introducing new products; it is about reaffirming our commitment to true Ayurveda. By holding on to the principles of Vidya (Knowledge), Vaidya (Learned Experts), and Vidhi (Processes), we ensure Ayurveda seamlessly fits into everyone’s daily life while staying true to its roots, crafted with expertise and designed to promote, lasting wellness.”

As AVP continues to evolve its product range, it remains committed to blending heritage with modern relevance. Among its latest standout offerings is Kesini Hair Care Range that constitutes Bringadi Thailam, an exotic Ayurvedic hair oil combining the goodness of 4 types of milk for promoting hair growth and restoring scalp health. The new category launch also features AVP Baby Oil, a formulation crafted with virgin coconut oil and carefully selected rare herbs. This nurturing blend supports infant skin care and strengthens the emotional bond between mother and child, reflecting AVP’s holistic approach to wellness through every life stage.

Strengthening the Commitment through Targeted Ayurvedic Solutions

As AVP expands into new wellness domains through innovative product lines, it continues to stay firmly rooted in its classical Ayurvedic expertise. The company’s commitment to evidence-based Ayurveda is reflected in both its time-tested formulations and scientifically validated solutions, ensuring that traditional wisdom remains at the core of its offerings.

Among the versatile formulations are Cervijith and Lumbajith Capsules, specialized Ayurvedic products that provide targeted relief. Cervijith is designed to provide focused relief for chronic neck pain and stiffness, promoting long-term comfort while Lumbajith offers targeted relief for lower back and spine discomfort, easing tension in the affected areas. These formulations, crafted to manage pain at its root, exemplify AVP’s expertise in chronic pain management, reflecting the brand’s deep understanding of Ayurvedic remedies tailored to contemporary issues.

AVP places great importance on research and science-backed data, ensuring that its formulations meet modern healthcare standards. One of their key formulations, Febrojith® exemplifies this evidence-based approach. A clinical study conducted at Medstar Specialty Hospital, Bangalore, validated Febrojith’s efficacy in significantly reducing body temperature and inflammatory markers, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). The study also demonstrated improvements in immune response, positioning Febrojith as a safer, more effective alternative to conventional antipyretics.

With scientific validation underpinning its formulations, AVP ensures that consumers benefit from safe, effective, and trusted remedies. While venturing into new segments and product categories, AVP’s focus on targeted, scientifically backed solutions continues to set it apart in the Ayurvedic healthcare space. In addition, AVP's 'Talk to Vaidya' initiative enhances customer service by offering a personal touch. Instead of automated responses, customers can directly interact with a qualified Vaidya, making the experience more personalised and special.
 

AVP: Over 120 years of legacy, Ayurvedic Excellence and Visionary Leadership

The Arya Vaidya Pharmacy (Coimbatore) Ltd. stands as a venerable institution in traditional Ayurveda, rooted in the principles of Vidya (Knowledge), Vaidya (Learned Experts), and Vidhi (Processes). These core values guide AVP's commitment to staying true to the science of Ayurveda. Nestled in Coimbatore, AVP boasts a widespread national and international presence, a network of esteemed physicians, manufacturing facilities, treatment centers, resorts, and academic resources. Dedicated to ensuring the accessibility of evidence-based Ayurvedic healthcare solutions, AVP has established specialised clinics and extensive community outreach programs globally.

Groundbreaking disease management protocols and a personalized approach to patient care serve as a testament to AVP’s dedication to making Ayurveda a cornerstone of holistic healthcare. The principles instilled by our esteemed founder, Aryavaidyan Shri P.V. Ramavarier, and mentor, Late Padma Shri P. R. Krishnakumar Ji, continue to guide and inspire AVP to reach new heights of distinction and excellence. AVP remains at the forefront of traditional Ayurvedic expertise, evolving into a symbol of comprehensive well-being in the modern world.
 

For more information, visit www.avpayurveda.com, email avpcare@avpayurveda.com, or call the toll-free number 1800 425 1522.
 

www.avpayurveda.com/product-category/new-age-formulation/

DDReg Pharma partners with Quantiphi to use power of Artificial Intelligence to datamine Regulatory Intelligence for efficient submissions, faster approvals and enhance compliance

Neeti Pant - DDReg Managing Director, said, “DDReg & Quantiphi collaboration harnesses DDReg’s unparalleled regulatory knowledge and Quantiphi’s innovative technology, along with a deep understanding of artificial intelligence, to revolutionize regulatory processes. Together, we are transforming how the life sciences sector navigates some of its most pressing regulatory challenges, ensuring compliance, enhancing safety, and accelerating the time to market for new therapies. This collaboration will not only address current regulatory demands but also anticipate future needs, providing a solid framework for sustainable growth and innovation. By combining our strengths, we are paving the way for a more streamlined, effective, proactive & cost-efficient approach to regulatory affairs in the life sciences industry.”

Quantiphi Global Head of Healthcare and Life Sciences, Barinder Marhok said the partnership marries DDReg’s expertise in global regulatory process management and securing and renewing government approvals for healthcare interventions with Quantiphi’s expertise in AI-managed processes and documents.

"As the life sciences industry grapples with the ever-evolving regulation landscape, Quantiphi and DDReg have come together to help deliver cutting-edge solutions that streamline regulatory processes across both the drug development and commercialization lifecycle, ultimately helping improve more lives,” Marhok said. “Leveraging cloud, data and AI technologies, our joint efforts aim to accelerate approvals, enhance compliance and optimize Life Cycle Management (LCM), ensuring a faster and more efficient path to market."

About DDReg

DDReg is a global Pharmaceutical Regulatory Services and Pharmacovigilance services provider company with offices in Gurgaon (India), Delaware, California (USA), Cologne (Germany), and Singapore. It is an ISO 9001:2015 & ISO 27001 TÜV SÜD certified organization that is involved in a wide variety of regulatory consulting and pharmacovigilance assignments. DDReg services span across global markets and include, European Union, the USA, UK & Australia among developed markets to Asia, Africa, Middle East & GCC, CIS, and LATAM among the emerging markets- driven by WHO.

DDReg has supported its clients in ensuring compliance with worldwide regulations for a wide range of products including generics, new drug products, biologics, biosimilars, medical devices & combination products, cosmetics, and consumer products. The team has deep subject matter expertise and a knowledge base of over 120 regulatory bodies for regulatory compliance. DDReg’s expansion strategy focuses on leveraging emerging technologies and expanding further into key international markets, especially those that have complex and/or ambiguous regulatory frameworks and growth of the pharmaceutical industry.

Follow us on LinkedIn, X, formerly Twitter and Facebook.

Product Packaging - Brinton's UV DOUX Lip Lightening Balm
 

The UV DOUX Lip Lightening Balm features a rich combination of Almond Oil and Hydrogenated Olive Oil, known for their natural lightening properties that help reduce dark spots and gradually restore lip’s original pigmentation. Coupled with Shea Butter, Cocoa Butter, and Mango Butter, the balm provides deep hydration, ensuring lips remain soft, smooth, and well-moisturized throughout the day.

Enhanced with Vitamin E and Grape Seed Oil, the balm offers antioxidant protection, promoting healthy lips and safeguarding them from environmental damage. The SPF 40 factor acts as a shield against harmful UV rays, preventing further pigmentation and sun damage, making it an essential part of any daily skincare routine.

Expressing enthusiasm, Mr. Rahulkumar Darda, CMD, Brinton Pharmaceuticals said, “We are excited to launch the UV DOUX Lip Lightening Balm in India as part of our ongoing commitment to creating innovative skincare products. Developed in collaboration with our Research Lab - Brinton Healthcare UK Ltd, this balm combines natural extracts with advanced sun protection to restore lips to their natural color while providing essential nourishment. Whether for sun-damaged or dehydrated lips, UV DOUX delivers the care needed to achieve the healthiest and brightest possible results.”

The balm’s lightweight, non-greasy and non-sticky formula ensures comfortable wear throughout the day, while its tint-free design makes it suitable for all genders. A subtle vanilla flavor adds a pleasant touch to the overall experience.

In line with BRINTON’s commitment to delivering high-quality skincare, this product further solidifies the brand’s reputation for creating dermatologist-recommended solutions that combine scientific research with natural ingredients. Known for its innovative approach to addressing skincare concerns, BRINTON continues to invest in research and new technologies to offer functionally safe and effective products that deliver visible results. The company prioritizes skin health and beauty with products that protect, repair, and nourish the skin. Known for its customer focus, it remains a trusted choice for high-quality skincare that boosts confidence. The company’s offerings include products such as sun protection, anti-aging and moisturizing items, as well as skin restoration products, and the quality of the products is excellent.

This dermatologist-recommended UV DOUX Lip Lightening Balm for darkened lips, which offers complete care for lip health, is now available on all leading online & retail stores.

UV Doux: Sunscreen Brand

UV Doux has earned its position as one of highest selling sunscreen brands in India, for its sun protection and skin health benefits. Formulated with advanced ingredients, UV Doux provides broad-spectrum protection against harmful UVA and UVB rays, preventing sun damage, premature aging, and hyperpigmentation. Dermatologist-recommended, this lightweight and non-greasy sunscreen is suitable for all skin types, making it a go-to solution for daily sun care.

About Brinton

BRINTON is dedicated to bridging the gap between everyday life and healthier choices. As an innovation-driven multinational company, BRINTON leverages over 500 years of collective experience in the healthcare industry to deliver high-quality, affordable products. With a strong global presence in 32 countries, BRINTON is committed to expanding its reach even further, transforming lives with its innovative healthcare solutions. The company offers a diverse range of therapies, focusing on key areas such as Dermatology, Cosmetology, Pediatrics, Gastrointestinal care, Respiratory health, and Rheumatology. BRINTON’s mission is to consistently develop cost-effective, efficient healthcare solutions that address the diverse needs of patients worldwide, ensuring improved health outcomes and a better quality of life for all.

The largest blood donation drive, sponsored by HAB Pharmaceuticals, took place in Chinchpokli and featured participation from 50 hospitals
 

Last week, HAB Pharmaceuticals and Tarun Mitra Mandal orchestrated an immensely successful blood donation event. The largest drive, sponsored by HAB Pharmaceuticals, took place in Chinchpokli and featured participation from 50 hospitals, including renowned institutions such as KEM, Wadia, Masina, Hinduja, and Saifee. The collective efforts resulted in the collection of over 5,000 bottles and 200,000 units of blood. Additionally, the drive expanded its scope to include the collection of stem cells and plasma, significantly enhancing its impact on public health.

The event also featured an awareness campaign for eye donation, aimed at educating the community about the importance of this noble cause. This comprehensive approach to health and wellness reflects the shared vision of HAB Pharmaceuticals and Tarun Mitra Mandal.

During the event, Mr. K.K. Agarwal and Mr. Sanjiv Garg, directors at HAB Pharmaceuticals, were felicitated for their significant contributions. Their leadership and steadfast support have been instrumental in driving the company’s CSR initiatives to success.

HAB Pharmaceuticals’ partnership with Tarun Mitra Mandal is a cornerstone of its CSR activities, reflecting the company's dedication to community health and well-being. This blood drive is just one example of the ongoing commitment to making a positive impact, and both organizations look forward to many such endeavors in the future.

By working hand-in-hand, HAB Pharmaceuticals and Tarun Mitra Mandal strive to address critical health needs and foster a culture of giving. Their collaborative efforts continue to make a tangible difference in the community, highlighting the powerful role that businesses can play in societal development.

Dr. Merin Dickson, Director - Medical Affairs, DocMode Health Technologies

With the launch of Clinical Research Services, DocMode aims to provide comprehensive solutions that encompass clinical trial management, data analysis, regulatory compliance, and more. This initiative will support pharmaceutical companies, healthcare providers, and researchers in conducting high-quality clinical studies efficiently and effectively.
 

DocMode's Clinical Research Services offer a broad range of capabilities. They include comprehensive management of clinical trials from study design to data collection and analysis, ensuring adherence to regulatory standards. Advanced biostatistical analysis and data management provide accurate and reliable results, while expertise in navigating complex regulatory environments ensures all studies meet necessary guidelines and standards. Additionally, the services include coordination and management of multi-center clinical trials to facilitate broader and more diverse patient recruitment and data collection.
 

In conjunction with this launch, DocMode announce the appointment of Dr. Merin Dickson as the Director of Medical Affairs. Dr. Dickson will lead the Clinical Research division, bringing extensive experience and a deep understanding of clinical research methodologies and medical affairs to the role. Dr. Dickson previously served as Chief Research Officer at Amrita Institute of Medical Science, where she managed multi-centric clinical trials and regulatory services for national biopharma missions.
 

"We are thrilled to launch our Clinical Research Services, which will play a crucial role in bridging the gap between clinical practice and research," said Hans Lewis, CEO of DocMode Health Technologies. "With Dr. Merin Dickson's expertise and leadership, we are confident that our new services will significantly contribute to the advancement of medical research and ultimately improve patient care.”
 

Dr. Merin Dickson also shared her enthusiasm about the new role, "I am honored to join DocMode at this pivotal moment. Our Clinical Research Services are designed to address the growing needs of the healthcare industry for robust and reliable clinical data. I look forward to working with our team and partners to drive impactful research that will shape the future of healthcare."
 

DocMode's Clinical Research Services are now available to clients in India and across the globe.

For more information, visit www.docmode.org.

Dr Kannan Vishwanatth FRSC Awarded Global Academic Researcher of the Year 2024

Dr Kanans Visvanats was felicitated at the power packed industry gatherings, policy makers & Academia in Mumbai on 18^th May 2024. Doyens of the industry debated critical international issues at the Leadership Conclave 2024. 

Prof. Dr Kanans Visvanats (Fellow of the Royal Society of Chemistry) has been recognized for his breakthrough research in oncology, highlighting his significant contributions to cancer research. His work in this field is aimed at developing innovative treatments and improving the understanding of cancer biology. Dr. Vishwanatth has been instrumental in the development of new cancer therapeutics. His research focuses on creating more effective and targeted treatments with fewer side effects compared to traditional chemotherapy.He has conducted extensive research on identifying and validating biomarkers for early detection and prognosis of various cancers. These biomarkers are crucial for personalized medicine approaches. Dr Kanans Visvanats’s work also explores the mechanisms by which cancers develop resistance to existing therapies. Understanding these mechanisms can lead to the development of strategies to overcome resistance.

Dr Kannan Vishwanatth, Member of Council at the Institute of Economics of The Latvian Academy of Sciences Riga

Dr Kanans Visvanats 's research often focuses on analyzing and developing economic policies that can drive sustainable growth. His work includes evaluating the impact of various economic policies on both national and global scales. He explores the relationship between technological innovation and economic development, studying how advancements in technology can spur economic growth and improve societal well-being. Dr Kanans Visvanats's work continues to influence the field of oncology, driving forward the development of more effective and personalized cancer therapies.

Prof. Dr Kanans Visvanats FRSC integrates environmental considerations into economic models, advocating for policies that balance economic development with environmental sustainability. Dr Kanans Visvanats has made significant research contributions primarily in the fields of pharmaceuticals, biotechnology, and environmental science. His work often focuses on the development of innovative solutions to complex problems, bridging the gap between theoretical research and practical applications. Here are some key highlights of his research contributions and notable publications:

Research Contributions:

Pharmaceutical Innovations:

Dr Kanans Visvanats has been involved in the development of novel drug formulations and delivery systems. His research aims to improve the efficacy and safety of pharmaceuticals.

Biotechnology Advancements:

He has contributed to the field of biotechnology through his work on genetic engineering, bioinformatics, and the development of biopharmaceuticals. His research often addresses the challenges of producing biologics and vaccines.

Environmental Science:

Dr Kanans Visvanats 's research includes studies on environmental pollution, waste management, and sustainable practices. He has worked on projects aimed at reducing industrial pollution and developing eco-friendly technologies.

Current Projects and Collaborations:

Dr Kanans Visvanats is involved in several interdisciplinary projects that aim to address global economic challenges at the institute of Economics of The Latvian Academy of Sciences. His collaborations often include international institutions, government agencies, and private sector partners, reflecting his commitment to applying research for practical solutions. Dr Kanans Visvanats is a leading researcher & on the board of Directors at the Institute of Economics of the Latvian Academy of Sciences. His role at this prestigious institution underscores his significant contributions to economic research and his influence in the academic community. Here are some key aspects of his work and contributions:

International Trade and Economics:

His research also delves into international trade dynamics, examining how trade policies and agreements affect economic relations between countries. Dr. Kannan Vishwanatth a passionate researcher with about 25 years’ experience in Pharmaceutical and International Trade. He has Received The Albert Schweitzer Medal For Science, The Malcolm Adiseshiah Award for Distinguished Studies 2020 and The Dr. APJ Abdul Kalam Excellence Award For Medicine. He Was Awarded the Academic Professional Award at American College of Dubai in UAE. He has co- authored and filed 15 world patents on products and various non infringing process in Anti-Malarial and Anti-Cancer products from Herbal Extracts with expertise in Licensing, Business Development, API, Generics, Finished Doses. Dr. Kannan Vishwanatth is a global Citizen & a strong believer in Corporate Social Responsibilities. Dr. Kannan Vishwanatth is a top academic researcher at the Garwood Innovation Fellow at Garwood Centre of Open Innovation, Haas School of Business Berkeley University of California & the Member of Council at the Institute of Economics of The Latvian Academy of Sciences Riga. Dr. Vishwanatth further pursued higher studies at the University of Azteca European Programs. Having mastered Chemical Engineering, Vishwanatth started his entrepreneurial journey a decade ago and formed a successful mid-sized pharmaceutical company with a major thrust on API (Active Pharmaceutical Ingredient). Dr. Kannan Vishwanatth has floated Dr Ashleys Herbals Limited, an independent herbal research firm that will function as a pioneer institute in the area of research, education, conservation, and popularization of Ayurveda medicinal plants.

Fortisil C

Collagen is a vital protein that helps to maintain the structure and elasticity of the skin, but as people age, their bodies produce less of it, leading to wrinkles, sagging skin, and other signs of aging. Fortisil C provides a potent and effective solution for improving skin health and appearance by using the power of marine collagen. With a unique formulation technology, Fortisil C is more effective at lower dosage of 2.5 gm. The product is available in effervescent form and 30 times more potent than standard collagen. It can improve skin hydration and skin elasticity within 2 months of usage because of its higher concentration of active dipeptides (Proli- hydroxyproline & Hydroxypoly - Glycine).

Fortisil C is very different from other collagen products available in the market because of its advanced formula, which includes a unique blend of amino acids, vitamins, and antioxidants that work together to nourish and replenish the skin. Additionally, each batch of Fortisil C is rigorously tested to make sure of its top-notch quality and purity, making it a safe and reliable choice for skincare enthusiasts. It’s pocket friendly and convenient to carry.

Speaking on the occasion, Mr. Sushant Raorane, Co-founder and Director of Adroit Biomed Ltd. said, “Adroit Biomed Ltd. as a science-driven company, we take pride in offering innovative & exceptional quality products. Wellnex High Performance Collagen in Fortisil C formulated with unique proprietary technology. Fortisil C is disrupted the collagen market & clinically proven to be 30 times more effective at lower dosage. We are extremely proud to launch Fortisil C.”

Dr Priya Talageri, Dermatologists said, “Currently available collagen products in the market have limited bioavailability & absorption. Today is the need of “High Performance Collagen” like Fortisil C.”

Dr Anju Methil, Dermatologists also stated, “Patient treatment compliance depends upon overall appeal of the product. Fortisil C High-Performance Collagen don’t have an obnoxious fishy smell like other collagen brands, which improves my patient compliance.”

About Adroit Biomed Ltd.

Adroit Biomed Limited is a pharmaceutical healthcare company with a focus on dermato-cosmetology. As a science-driven company they offer exceptional quality products that inspire real change in the world of dermatology. These products are manufactured using the state-of-the-art formulation manufacturing facilities, adhering to international standards and regulations.

Using world class ingredients and the latest technology the company aims at delivering the highest quality products and forming an interface between innovation, technology, healthcare practitioners and patients.

Website: adroitbiomed.com.

VAV Lipids EU GMP certified facility at Ratnagiri

VAV’s upgraded EU cGMP-certified manufacturing facility at Ratnagiri, India, can produce 6,000 kilograms (6 tonnes) of egg lecithin annually. This is about 7% of the estimated annual global demand of 85,000 kilograms (85 tonnes).

The development puts VAV and India on the global list of select suppliers for this high-grade ingredient.

Propofol is an intravenous medication used for inducing anaesthesia before surgery. Propofol formulations contain natural triglycerides like soybean oil and egg lecithin, a fatty substance from egg yolk. Both are crucial ingredients that enhance the biocompatibility of the medication.

Speaking about the demand for high grade ingredients, Arun Kedia, Managing Director of VAV Lipids, said, “Propofol is an important medication as it dominates the general anaesthesia market. We have seen a rising demand for egg lecithin from propofol manufacturers not only from India but all over the world. I am happy that VAV has stepped up to fulfil their requirements, thus ensuring a robust supply chain.”

According to a report published online on the general anaesthesia market, propofol leads the segment with over 25% market share. The report estimates the global general anaesthesia drugs market size to be about US$ 4,978 million with a projected CAGR of 3.3%.

Other reports suggest that the global egg yolk lecithin Market may reach US$ 386.6 million by 2030 with a CAGR of 6.4%.

VAV Lipids is headquartered in Mumbai, India and is among the world’s leading manufacturers of phospholipids and lecithin. The biopharmaceutical company manufactures plant phospholipids (LECIVA), egg phospholipids (LIPOVA), synthetic phospholipids, and neutral lipids. The other products include APIs and specialty proteins. 

VAV’s high-grade phospholipids and lecithin are functional ingredients in developing novel drugs and biologics delivery systems (NDDS). Pharmaceutical companies use its high-quality lipids and lecithin to create multiple drug and biologics delivery projects. These include applications of lipids in developing vaccines, anaesthesia and formulations, cancer therapy based on liposomes, and novel drug delivery systems for treating several diseases. The products are also used in skincare, personal care and hair care products.

Biopharma experts come together at Avantor Biopharma Forum to discuss challenges of biologics manufacturing and its future evolution

The Indian biopharmaceutical industry is rapidly expanding with increased investments in research and development, robust product pipelines, collaborations, and technological advancements. However, challenges such as constantly evolving regulatory compliances and price and quality control impede global competitiveness. The 2024 Avantor Biopharma Forums focused on critical topics including scale-up, risk mitigation, and cost optimization, which are crucial for addressing these challenges and driving growth in the biopharma industry.
 

With the goal of facilitating an enriching exchange of ideas for professionals within India’s Bioprocessing industry, the forums provided a platform for over 600 participants from some of the prominent biopharma players in India to engage with Avantor's products and solutions, fostering knowledge exchange and collaboration within the bioprocessing community.
 

Biopharma specialists and team from Avantor at the Avantor Biopharma Forums held at Bengaluru, Hyderabad and Pune
 

The highlight of the forums was industry panel discussions with biopharma experts from leading biotechnology and biopharmaceutical companies across the three cities. These discussions explored topics such as the current state-of-the-art in biologics manufacturing, overcoming critical challenges associated with process failure or yield, and the future evolution of biologics manufacturing and digital advancements across the industry

• Dr. Ger Brophy, Chairman of Avantor’s Scientific Advisory Board, spoke about the Readiness for Changing Biological Molecules and Regulatory Environment⁽¹⁾ and shared his perspective about the ever-evolving regulatory environment in the country.

• Highlighting the evolution of the industry, Mr. Narayana Rao Rapolu, VP, Biopharma and Applied Products Solutions, said, “The Indian biopharma sector is witnessing a rise with the introduction of high-quality, cost-effective biosimilars into the market. At Avantor, we recognize the significant challenges hindering the growth of biopharma companies. With innovative strategies emphasizing efficiency, quality, and affordability, we aim to generate a positive impact on the biopharma business while earning the trust of our customers.”

• Dr. Nandkumar Deorkar, SVP Research and Development, Avantor, shared his insights about the effective management of Total Cost of Ownership in Bioprocessing. “At Avantor, we work to simplify our customers’ scale-up processes thereby eliminating process steps. Avantor’s objective is to create long- term, strategic partnerships within the industry by working closely with biomanufacturers to drive and foster cost optimization and improve biologics process efficiencies. We are proud to provide exceptional post-sales support and quality assurance, both are key decisive factors in for driving the success of at biopharma companies,” said Dr. Deorkar.

The Avantor Biopharma forums were hugely successful in bringing the industry together for meaningful dialogue and exchange. The participants were appreciative of the knowledge sharing sessions and engaging conversations.

About Avantor

Avantor^®, a Fortune 500 company, is a leading life science tools company and global provider of mission-critical products and services to customers in the life sciences and advanced technology industries. From discovery to delivery, we work side-by-side with scientists around the world to enable breakthroughs in medicine, healthcare, and technology at scale. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries.

For more information, visit avantorsciences.com and find us on LinkedIn, X(Twitter) and Facebook.

(1) Biopharma forum in Bengaluru.

Retail Expansion on the Horizon: 200 Outlets by 2025

Boasting a current network of 25 retail outlets in Kolkata and adjoining districts, Pharmacy Bazar sets forth its vision for expansive growth, aspiring to establish an additional 200 retail outlets by the close of the fiscal year 2025. This strategic endeavor underscores Pharmacy Bazar's unwavering commitment to providing convenient access to healthcare products and services across diverse communities in the region.

Exclusive Benefits through ICICI and AU Bank Partnership

Pharmacy Bazar is excited to unveil a strategic partnership with ICICI Bank and AU Bank, ensuring exclusive benefits for nearly one crore AU Small Bank customers and nearly 10 crore ICICI Bank customers. This collaboration aims to enhance customer convenience and savings to unprecedented levels. ICICI Bank and AU Bank account holders are entitled to a range of exclusive benefits, including:

1. A generous flat 25% discount on all medicine purchases made and extra 2% discount for ICICI Bank Bank debit or credit card holders.

2. An additional upto 2% discount facilitated by a unique coupon code exclusively crafted for AU Small Finance Bank’s customers.

3. Accumulation of reward points in accordance with ICICI Bank & AU Bank's debit and credit card policies.

This strategic collaboration reinforces Pharmacy Bazar's commitment to continually enhance customer experiences and provide access to affordable healthcare solutions. The team eagerly anticipates a seamless and prosperous journey with ICICI Bank & AU Bank, aiming to further elevate its services for the benefit of its valued customers.

Pharmacy Bazar - Elevating Healthcare, Enriching Lives.

With a strong commitment to delivering quality IVD solutions at a reduced cost, Lords Med has successfully built a vast network of over 300 distributor channels across India. The manufacturing facilities located in the outskirts of Mumbai, currently has the capacity to facilitate more than 1.7 crore diagnostic tests per month, covering a wide range of specialties including biochemistry, haematology, serology, rapid tests, and urine strip tests.

Mr. Manav Teli, Executive Director, Lord’s Mark Industries Ltd.

Commenting on the launch, Mr. Manav Teli, Executive Director, Lord’s Mark Industries Ltd. said, “We are thrilled to announce our presence across borders with successful export of diagnostic supplies int Nepal and Bangladesh. Our goal has always been to emerge as a global leader in IVD manufacturing and export, providing top-quality solutions at an affordable cost. With our advanced manufacturing facilities and extensive distributor network, we are now expanding our reach to neighbouring countries. This marks a significant milestone in our journey towards meeting the healthcare needs of a wider population. We are also excited to explore OEM opportunities and further scale up our manufacturing capacity, ensuring accessible diagnostics for all."

As Lord’s Mark Industries continues to strengthen its presence in the Indian market, the company is now strategically focusing on supplying neighbouring countries with its high-quality IVD products. The conglomerate currently has five companies: Lords Med, Lord’s Mark Biotech, Lord’s Mark Micro-biotech, Brahamastra Defense Techno Products Limited, Lord’s Mark Insurance Broking Limited, and Lord’s Automative Private Limited, with other verticals in renewable energy products and paper.

About Lord’s Mark Industries
Incorporated in 1998, Lord’s Mark Industries Private Ltd. (Lord’s) has made impressive growth starting from paper to LED to Renewable energy and making grand in the medical diagnostic industry. Lord’s and its subsidiaries have made a mark in Electric Vehicle, Genome Testing, Vitamin Industry and Healthcare. Growth through diversification has become the trend setter and has been the cornerstone of success at Lord’s.

Website - lordsmark.com.

About LordsMed

LordsMed, the global healthcare division of Lords Mark Industries Pvt. Ltd, aims to become an integrated healthcare provider offering quality products in verticals encompassing therapeutic care (chronic & acute), hygiene care, pharma distribution, diagnostics and safety essentials. Lords Med is a manufacturer of In- Vitro Diagnostic test kits, Semi Autoanalyzer, Haematology machines, Rapid kits, Biochemistry Reagents k and Special Parameter used mostly by all government organisations, hospital (public and private) and labs via 400 plus strong distribution network Pan India. Lords Med is a manufacturer of in vitro diagnostic kits for COVID-19 (antigen and antibody), malaria and dengue. It is an authorized distributor partner of medical devices like health tracking. The division has more than 60 registered brands across chronic & acute care. Our R&D research team is constantly under development of new and unique products which can be useful to the public. lordsmed.com.

Mankind Pharma’s Consumer Health Division, a prominent player in India's health and wellness sector with brands like Manforce, Prega News, Gas-O-Fast, Health OK, and AcneStar has become a part of the Open Network for Digital Commerce (ONDC). With this, Mankind Pharma has expanded its network for buyers and customers to access its wide range of products.
 

Leveraging retail intelligence firm Bizom’s Seller Platform, Mankind Pharma's extensive product catalogue is now effortlessly within reach for buyers across the ever-expanding ONDC Network
 

Leveraging Bizom’s Seller Platform, Mankind Pharma's extensive product catalogue is now effortlessly within reach for buyers across the ever-expanding ONDC Network. This integration will help with the widespread visibility of Mankind Pharma's brands on every buyer app within the network, presenting consumers with an unparalleled and widespread shopping experience marked by utmost convenience.
 

The consumer health division is a rapidly expanding segment of Mankind Pharma, having achieved a compounded annual growth rate (CAGR) of approximately 22% in FY21-23. By joining the ONDC Network, the division looks to strengthen its nationwide presence after having already established the division as a market leader in consumer healthcare products.
 

ONDC has been successful in disrupting the e-commerce industry in the country and Mankind Pharma will seek to add invaluable medical products to the extensive range of offerings that the home-grown e-commerce network currently offers to its user base. With this, Mankind Pharma envisions creating numerous consumer touchpoints through innovations within the ONDC Network.
 

“ONDC is built to empower all kinds of businesses to attain a deeper penetration into the consumer market without any entry barriers. Mankind Pharma getting onboard will serve as a key addition to the health and wellness category on our Network. With more major brands joining us, it solidifies the inclusive nature of the open network that will further boost innovation and economic opportunities for millions,” said Shireesh Joshi, CBO, ONDC.
 

Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical companies in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing international quality products at affordable prices.
 

The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas. This includes products for anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, VMN and respiratory diseases, among others with a strategy to increase market presence/share for chronic ailments. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. The company has 25 manufacturing facilities across India and has over four thousand manufacturing personnel as of December 31, 2022. Manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products.
 

Mankind has a consistent track record of product innovation. As of December 31, 2022, the company had a team of over 600 scientists and dedicated in-house R&D centres with six units located in Haryana, Maharashtra, Himachal Pradesh and Uttarakhand.
 

For more information, visit www.mankindpharma.com.

About ONDC

Incorporated on 31st December 2021, Open Network for Digital Commerce (ONDC), a Section 8 company, is an initiative of the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India to create a facilitative model that revolutionises digital commerce, giving greater thrust to penetration of retail e-commerce in India. ONDC is not an application, platform, intermediary, or software but a set of specifications designed to foster open, unbundled, and interoperable Open Networks.

About Bizom

Bizom is the Retail Intelligence Platform that digitises global distribution engines, with AI-based, outcome-driven sales automation tools like Bizom SFA, Bizom DMS, and Bizom Retailer App. With a keen focus on revolutionising the distribution landscape in emerging markets, Bizom’s advanced solutions aim to empower retail businesses to optimise their distribution networks, enhance supply chain efficiency, optimise inventory management, and enhance overall sales and operational performance.
 

Implemented across 50+ countries for more than 600 leading retail brands and 8 million stores, Bizom empowers each stakeholder in the downstream supply chain with intelligent analytics to place the right products at the right outlets.

Raj Prakash Vyas receiving award for Cadila Pharmaceuticals Ltd.
 

A distinguished panel of experts selected Cadila Pharmaceuticals for this accolade, underscoring the company's unwavering dedication to pioneering advancements in the pharmaceutical industry.
 

On December 15, Raj Prakash Vyas, President of Corporate Affairs at Cadila Pharmaceuticals, received the award on behalf of the company in a ceremony attended by key opinion leaders and notable figures from India's corporate realm. The event was graced by esteemed personalities such as Dr. Parvinder Maini, Scientific Secretary at the Office of the Principal Scientific Adviser to the Government of India, Vipin Sondhi, Chairman of CII Industrial Innovation Awards 2023, and Alok Nanda, Co-chairman of CII Industrial Innovation Awards 2023.
 

Among the groundbreaking innovations from Cadila, showcased were Rabeloc IV, Sepsivac, Polycap, Resorine, Cadiflu, MycidacC, ThRabis, and others. These innovations, Mr. Vyas emphasized, represent the company's commitment to advancing healthcare solutions that have the potential to reshape the landscape of public health in India.
 

"At Cadila Pharmaceuticals, our focus on innovation is not just about creating medicines; it's about catalyzing positive change. Our innovations are designed to address critical public health problems, contributing to a healthier and more resilient society," affirmed Mr. Vyas.
 

The CII Industrial Innovation Awards, instituted in 2014, serve to identify and celebrate innovative enterprises across diverse industry segments in India. These awards provide a platform for companies to gain national and international recognition for their innovative products and services. Recognized as one of the most coveted innovation awards in the country, the CII Industrial Innovation Awards not only honor innovation champions in Indian industry but also enhance their competitiveness in both domestic and global markets. Cadila Pharmaceuticals stands proud as a beacon of innovation in the pharmaceutical landscape, embodying excellence and commitment to healthcare advancement.

Cadila Pharmaceuticals is a global pharmaceutical company with a rich history of over seven decades. Established in 1951, the company has consistently focused on creating innovative and affordable healthcare solutions for people worldwide. With a strong commitment to ethics, quality, and integrity, Cadila Pharmaceuticals strives to make a positive impact on healthcare delivery, driving its mission to provide affordable and accessible medicines for a healthier world.

For more information, please visit our website www.cadilapharma.com.

Speaking at the summit, Dr Ruchi Sogarwal, Head of Corporate Affairs, Takeda Biopharmaceuticals India Pvt Ltd, said, “South Asian countries have experienced substantial outbreaks of vector-borne infectious diseases which makes the need for newer prevention modalities including vaccine no longer a choice but a strategic imperative. The formation of cross sectoral multi-stakeholder alliances is required to deliver a new collaborative model for accelerated R&D, scale up of vaccines production, leveraging technology for more resilient supply chain networks, and enabling systems for equitable and cost-effective vaccine delivery. Besides that, proactive engagement of civil society organizations is essential to enhance the uptake of such disease prevention modalities across different geographies and epidemiological settings.”

Gopal Agarwal, Head of Market Access and Pricing, Takeda Biopharmaceuticals India Pvt. Ltd., added, “As vector borne diseases continue to put increasing financial strain on the already stretched healthcare systems of today, innovative financing becomes indispensable. By fostering public-private partnerships and harnessing impact investments, we can reshape the landscape of disease prevention and control to create a healthier future for at-risk populations.”

The AVPN South Asia Summit December 2023 brought together social impact thought leaders and industry experts from South Asian countries who engaged in decisive dialogues strategically aimed at identifying innovative partnership avenues and steering collective efforts for advancing positive change.

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.

For more information, visit www.takeda.com.

Retail Expansion to Reach 200 Outlets by 2025
 

Pharmacy Bazar currently boasts a network of 25 retail outlets across Kolkata and neighboring districts. Building on this strong foundation, the company plans to significantly expand its reach, aiming to open an additional 200 retail outlets by the end of fiscal year 2025. This expansion reflects Pharmacy Bazar's commitment to providing convenient access to healthcare products and services for communities throughout the region.
 

Partnership with Axis Bank Offers Exclusive Benefits
 

Pharmacy Bazar is proud to announce a strategic partnership with Axis Bank, aimed at enhancing customer convenience and savings. Axis Bank account holders can now enjoy:

1. 20% flat discount on all medicine purchases made through Axis Bank debit or credit cards.
2. Additional 2% discount using a special coupon code designed exclusively for Axis Bank customers.
3. Reward points accumulated as per Axis Bank's debit and credit card policy.

This partnership underscores Pharmacy Bazar's commitment to continuously improve customer experience and provide access to affordable healthcare solutions.The team looks forward to an "endless and effortless journey" with Axis Bank and to further enhance its services for the benefit of its customers.

Takeda today announced the signing of a three-year MoU with the Biotechnology Industry Research Assistance Council (BIRAC) (birac.nic.in), a public sector enterprise set up by the Department of Biotechnology, Government of India. The MoU was announced in the presence of Dr. Jitendra Singh, Hon’ble Union Minister of State for Science & Technology, Minister of State for the Prime Minister Office, Government of India, and senior government and industry leaders. The partnership will allow Takeda to extend advisory and mentoring support to innovators and entrepreneurs while assisting them from ideation to market deployment of new-age healthcare solutions. The collaboration resonates with BIRAC’s vision to stimulate, foster and enhance the strategic research and innovation capabilities of the Indian biotech industry for creation of affordable products addressing the needs of the largest section of society.

Speaking of the collaboration, Sanjay Patel, Global Head of Data Digital and Technology Innovation Capability Solutions, Takeda Pharmaceuticals International AG, said, “India is a vibrant and promising healthcare market. The country’s healthcare segment offers an incredible opportunity both for innovation and growth. The entrepreneurial spirit of domestic healthcare startups has the power to drive healthcare advancements not only in India but globally. This partnership between Takeda and BIRAC, thus, moves beyond convention, signifying a promise to further healthcare in a manner that sets the stage for lasting improvements in the years to come.”

Serina Fischer, General Manager, Takeda Biopharmaceuticals India Pvt. Ltd. said, “At Takeda, we are committed to meeting the unmet needs of patients by discovering and delivering life-transforming treatments and innovative solutions. Our vision and mission align with the Indian Government’s aspiration for local solutions to global healthcare challenges. This partnership serves as a practical blueprint, highlighting how public and private players can join forces to propel substantial and enduring advances in healthcare.”

Ruchi Sogarwal, Head of Corporate Affairs, Takeda Biopharmaceuticals India Pvt. Ltd., added, “Collaborations between the government, academia and industry contribute immensely to accelerating innovation and building disruptive healthcare technology solutions for addressing unmet patient needs. Our partnership with BIRAC will allow us to foster innovations, nurturing capabilities and enhancing global competitiveness translating bioscience into bioeconomy.”

The partnership was announced at the Global Bio-India (GBI) 2023 (www.globalbioindia.org) event organized by the Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India and its Public Sector Undertaking, BIRAC. GBI is a mega international congregation of biotechnology stakeholders, including international bodies, regulatory bodies, Central and State Ministries, SMEs, large industries, bioclusters, research institutes, investors, and the startup ecosystem.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof.

These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

Dr. Sujeet Kumar Singh at the Convocation Ceremony

Speaking on this Dr. Sujeet Kumar Singh said at the convocation ceremony “I am truly honored and humbled to accept this honorary doctorate degree conferred on me by the Sunrise University Alwar Rajasthan. I am really touched by the overwhelming reception extended to me during the ceremony. I have been truly blessed to be a part of this prestigious recognition and It’s been my absolute privilege to meet and interact with the esteemed faculty and the bright students at the Sunrise University Alwar Rajasthan.”
 

Recently Flawless Pharma has been in the news for its willingness to invest USD 100 Million in buyout of Assets & Patents in Hong Kong and China & its collaboration & partnership with regard to the API Deal with European and African Company for USD 120 Mn.
 

Dr. Sujeet Kumar Singh, Managing Director, Flawless Pharma Pvt. Ltd.
 

Dr. Sujeet Kumar Singh is a Global Entrepreneur who comes with a Decade old extensive experience in the pharmaceutical domain from conceptualization, and research to Launching finished goods and establishing one of its own kind brands with all necessary government certifications. He pursued a Master in International Business Management and currently leading Flawless Pharma Pvt Ltd as Promoter and Managing Director. He spent 2 decades in the Middle East, Russia, Africa, Saudi Arabia, Oman, and Keniya and did extensive research about the challenges, and solutions for specific markets and derived aggressive business models which interns catered maximum market shares in the region and became one of its own kind Brand in the Global Market space. With his baggage full of international exposure in brand building, he returned to India and ventured into Flawless Pharma in 2020. Due to his Exceptional knowledge and Expertise, the European Institute of Applied Research awarded him with an Honorary Doctorate Degree in 2017. From a startup to a Brand in making at Globe, is his Exceptional achievement in Flawless Pharma. Under his supervision, Flawless Pharma has seen steep and steady growth with a larger market spread in no time.

Dr. Sujeet Kumar Singh, Managing Director, Flawless Pharma Pvt. Ltd.
 

Flawless Pharma’s product basket focuses on APIs & advanced intermediates in multiple therapy area with deep technical and scientific knowledge established over the last five years, such as Analgesic, antipyretic and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand. Flawless Pharma is one of the fastest-growing pharmaceutical companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 50 countries worldwide. For more than 10 years, Flawless Pharma has been offering API (Active Pharmaceutical Ingredient) manufacturing & Marketing services, from process development to commercial manufacturing in full regulatory compliance, to ensure a robust and secure supply chain of Pharmaceutical APIs.
 

Announcing the Collaboration & Technology Transfer Agreement Dr Sujeet Kumar Singh, Managing Director of Flawless Pharma Pvt. Limited said “We are pleased to announce the partnership with the two of the top European & African Pharma Company to supply of the active ingredient of the Anti-cancer and Anti-viral drugs with a technology transfer agreement. The combined value of the deal will be to the tune of US $ 120 Mn. Our new collaboration with the European & African market demonstrates Flawless Pharma’s deep commitment to making equitable and affordable access to Anti-cancer and anti-viral drugs through the collaborative technology transfer agreement a reality for people living with multi prolonged diseases in low- and middle-income countries which will transform communities and make life better for people throughout the continent. Flawless Pharma is committed to empowering the fight for health and well-being as a fundamental human right through our partnerships & collaborations. Flawless Pharma will supply its active pharmaceutical ingredient (API) for the Anti-cancer and Anti-viral drugs at a significantly reduced price to both the companies based out of Europe & Africa. Flawless will also provide technology transfer to enable the companies establishing the company as a trusted manufacturer of these lifesaving products in Africa.”
 

Flawless Pharma Pvt. Limited, headquartered at Mumbai in India is one of the fastest growing pharmaceutical company focusing on the development, manufacturing, and sale of high quality and affordable process R&D and API manufacturing service providers for the worldwide pharmaceutical industry since 2010. Flawless Pharma Private Limited has uniquely integrated development, regulatory, and manufacturing capabilities & has offices in Dubai, Singapore, Hong Kong. Flawless Pharma Private Limited offers a wide portfolio of services ranging from API’s for the generic industry to custom synthesis for early phase pharmaceutical research and branded products. Flawless Pharma Pvt. Limited is a customer-focused backwards-integrated world-class developer, manufacturer & trading of Active Pharmaceutical Ingredients (APIs). It is the independent company of choice in collaboration with leading producers of advanced API solutions with state of manufacturing facilities with stringent operating procedures and compliance to current Good Manufacturing Practices (cGMP) and applicable regulatory requirements and reliable supply to gain sustainable competitive advantage. Flawless Pharma Pvt. Limited has a wide basket of portfolio includes over 300 APIs across multiple therapeutic segments with marketing presence in over 50 countries in Middle East, European and African countries.

Harshit Jain MD, Founder & Global CEO, Doceree
 

Driven solely by the mission to transform healthcare professional (HCP) marketing globally, the funds will enable Doceree to accelerate product development, augment technologies, scale global expansion, and expand team.

Founded in 2019, Doceree empowers pharmaceutical and life-sciences companies and healthcare media agencies with solutions that seamlessly reach HCPs on their networks and within their digital workflows, to achieve better patient health outcomes. The company, with its largest global network of HCP-only digital platforms, has made rapid strides in HCP communications through its programmatic messaging capabilities, to help clients across the globe maximize performance of their physician engagement initiatives.

“We are pioneering HCP messaging solutions that are first to market. It is incredible to watch our innovative products disrupt the space and drive adoption of programmatic technology in the life-sciences industry, not just in evolved markets like the US, but also elsewhere in the same vein. We have been able to simplify HCP engagement globally with our unique AI-enabled proprietary technology and offer quality end-to-end HCP-targeting solutions that have helped our clients succeed with profitable growth. The pharma messaging space is evolving at a fast pace and our solutions are aligned to meet the immediate requirements of the life sciences industry. The investment speaks volumes about the value we are creating in the space,” said Harshit Jain MD, Founder & Global CEO, Doceree. Jain further added, “We are growing massively and have competitive edge. We are thrilled about the future as we continue to expand and touch new horizons in the space.”

Doceree has grown more than 100% in the last one year with monthly revenue rising five folds between the Series A funding in April 2022 and now. The company has introduced category-first innovations on the demand and supply sides, including Doceree Enterprise, an HCP-focussed global Demand Side Platform (DSP), and Doceree Provider that empowers HCPs to improve health outcomes of their patients. Its HCP marketing ecosystem consists of custom-built solutions that equip life science marketers to engage with physicians at opportune moments with contextual messaging and evaluate campaign performances to improve script lift.

Prakash Parthasarathy, Managing Partner & CIO and Nitish Bandi, Partner, Creaegis, said, “We are excited to partner with Harshit and the Doceree team to support the company in its next phase of growth led by an industry leading digital platform driven by deep learning-based data models. Our past experience of investing in pioneering global SaaS companies and in the healthcare ecosystem will enable us to support the company’s mission to create superior outcomes for pharma brands, providers and patients.”

On the back of the huge response to its solutions in the US, India and the European markets, Doceree expanded its footprints to Africa, Southeast Asia (SEA), and the Gulf Cooperation Council (GCC), curating and iterating solutions that serve the specific needs of marketers in these regions.

“Doceree’s technology platform allows biopharmaceutical companies to connect with physicians like never before. The company’s impressive growth trajectory is an outcome of its unique, data-driven approach to enable communication with precision and relevance. It has been exciting to partner with Harshit and the team since their Series A round, and we are thrilled to continue supporting their pioneering work,” Ashish Venkataramani, Partner, Eight Roads Ventures.

A line-up of smart and connected solutions from Doceree’s product portfolio are awaiting launch in the months to come that will bring massive transformational change to the entire ecosystem globally. The products will facilitate HCP targeting like never before, enriching communications at multiple HCP touchpoints in the professional and clinical journeys of physicians.   

Investec advised Doceree on the Series B transaction.

About Doceree

Doceree is a global platform building unique solutions for healthcare professional (HCP) programmatic messaging with proprietary data tools. It facilitates messaging between life sciences brands and HCPs through an extensive global network of digital endemic and point-of-care platforms to programmatically deliver personalized communications to HCPs at scale.

To learn more, visit doceree.com.

About Creaegis

Creaegis is a growth investment firm focused on digital and technology businesses with a team history of investing in some of the digital pioneers in India and the US. The firm recently invested in companies such as Kale Logistics (Enterprise SaaS), Zopper (InsurTech) and Medikabazaar (HealthTech).

To learn more, visit creaegis.in.

About Eight Roads Ventures

Eight Roads Ventures is a global venture capital firm backed by Fidelity, with offices in India, China, Japan, and UK. Our 50-year history of investing includes partnerships with over 300 healthcare and technology companies. Eight Roads Ventures’ India healthcare portfolio includes Ashish Life Science, Bicara Therapeutics, Caplin Steriles, Carestack, Cipla Health, Core Diagnostics, Doceree, eKincare, Eywa Pharma, Elucidata, Enzene Biosciences, Enko, Everheal, Immuneel Therapeutics, Laurus Labs, Medwell Ventures, NOCD, Plasmagen Biosciences, Proximie, OZiva, PharmEasy, Richcore Lifesciences, Specsmakers, Spry, Toothsi, Trivitron Healthcare and Ujjala Cygnus.

To learn more, visit  www.eightroads.com.

AMAI Office Bearers

Mr Virmani, a chartered accountant by qualification, and a veteran of the industry has had long innings of two decades in the textiles sector before moving to chlor-alkali industry. In the last two years, Mr Virmani has served the industry as Vice President of AMAI and has mentored the post-COVID recovery process of the industry through meaningful dialogue with the Government and organization of insightful industry sessions.

Young and dynamic Aditya Shriram, with a degree in Industrial Engineering from the prestigious Cornell University and an MBA from the London Business School, is heading the Chemicals Business in the diversified ~ INR 12000 cr. DCM Shriram Group. The Chemicals Business has invested more than INR 3500 Cr, including in new growth areas, and has become an important vertical for driving growth within the Group.

Following the AGM was release of a book titled “Caustic Courage: The Memoir of a Chemical Engineer” by P N Ojha, a veteran of the chlor-alkali industry.

AMAI represents producers of caustic soda, chlorine, soda ash, PVC, CPVC and a few other related products which are an important segment of the chemical industry, providing inputs which find wide spread usage in a diverse range of industrial and consumer goods. The industry has espoused the spirit of Make in India and has been meeting most of the country’s needs for a long time against all odds including the onslaught of cheap imports. Major end use areas for caustic soda are in soaps & detergents, pulp & paper, textiles and aluminium processing and for soda ash in glass, silicate production, etc. apart from soaps & detergents. Major uses of chlorine are for the production of PVC apart from usage in water purification.

During the outbreak of COVID, AMAI members served an important role as they closely aligned with the Government for ensuring adequate supply of disinfectants. The industry enhanced the production of sodium hypochlorite, chlorine, bleaching solution/powder, etc. the major chemicals used extensively for disinfection and preventing the spread of COVID.